<SEC-DOCUMENT>0001645113-24-000036.txt : 20241217
<SEC-HEADER>0001645113-24-000036.hdr.sgml : 20241217
<ACCEPTANCE-DATETIME>20241216195438
ACCESSION NUMBER:		0001645113-24-000036
CONFORMED SUBMISSION TYPE:	8-K/A
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240830
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241217
DATE AS OF CHANGE:		20241216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NovoCure Ltd
		CENTRAL INDEX KEY:			0001645113
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37565
		FILM NUMBER:		241553314

	BUSINESS ADDRESS:	
		STREET 1:		NO. 4 THE FORUM
		STREET 2:		GRENVILLE STREET
		CITY:			ST. HELIER
		STATE:			Y9
		ZIP:			JE2 4UF
		BUSINESS PHONE:		44 (0)15 3475 6700

	MAIL ADDRESS:	
		STREET 1:		NO. 4 THE FORUM
		STREET 2:		GRENVILLE STREET
		CITY:			ST. HELIER
		STATE:			Y9
		ZIP:			JE2 4UF

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novocure Ltd
		DATE OF NAME CHANGE:	20150615
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K/A
<SEQUENCE>1
<FILENAME>nvcr-20240830.htm
<DESCRIPTION>8-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8a1f6b7d-0ca3-4369-ad4c-e8a2ec75a71f,g:41cf253c-f72f-4fea-b849-5125654aacb5,d:5ac6acc1b2004ea8a4783938a6eacdb8-->
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>nvcr-20240830</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-21">0001645113</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-22">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="nvcr-20240830.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001645113</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-26</xbrli:startDate><xbrli:endDate>2024-10-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i5ac6acc1b2004ea8a4783938a6eacdb8_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:174%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:144%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K/A</ix:nonNumeric> </span></div><div style="margin-top:11pt;padding-left:108pt;padding-right:108pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:1pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">August 30, 2024</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date of Report (date of earliest event reported)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">NovoCure Limited</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:144%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:420.75pt"><tr><td style="width:1.0pt"/><td style="width:160.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:49.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:153.25pt"/><td style="width:1.0pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-4">Jersey</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-37565</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">98-1057807</ix:nonNumeric></span></div></td></tr><tr style="height:23pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">No. 4 The Forum, Grenville Street</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">St. Helier</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-9">Jersey</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">JE2 4UF</ix:nonNumeric></span></div></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%">+<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">44 (0) 15</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">3475 6700</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Registrant's telephone number, including area code</span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span><br/></span></div><div style="padding-left:5.62pt;padding-right:5.62pt;text-align:center"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-13">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-14">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-15">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></div><div><span><br/></span></div><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:33.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Ordinary Shares, no par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">NVCR</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="text-align:right"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span></div><div style="text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i5ac6acc1b2004ea8a4783938a6eacdb8_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span><br/></span></div><div style="-sec-extract:summary;margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Explanatory Note</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Current Report on Form 8-K/A (this &#8220;Amendment&#8221;) is being filed by NovoCure Limited (the &#8220;Company&#8221;) to amend the Current Report on Form 8-K filed with the Securities and Exchange Commission on September 3, 2024 (the &#8220;Initial Form 8-K&#8221;), solely to supplement the Company&#8217;s disclosure under Item 5.02 of the Initial Form 8-K. This Amendment provides a description of (i) the compensation of Ashley Cordova in connection with her appointment as Chief Executive Officer effective as of January 1, 2025 and (ii) the compensation of Asaf Danziger in connection with his transition from Chief Executive Officer of the Company to Senior Advisor to the Chief Executive Officer. At the time of the filing of the Initial Form 8-K, the compensation in connection with Ms. Cordova&#8217;s appointment and Danziger&#8217;s transition had not yet been determined. This Amendment does not otherwise modify or update any other disclosures in the Initial Form 8-K.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#8239;5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cordova Employment Agreement </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with her appointment as Chief Executive Officer, on December 11, 2024, Ms. Cordova entered into a new employment agreement with a subsidiary of the Company (the &#8220;Cordova Employment Agreement&#8221;), effective January 1, 2025. Under the Cordova Employment Agreement, Ms. Cordova will receive an annual base salary of CHF 750,000 per year. In addition, Ms. Cordova is eligible to receive a discretionary annual cash bonus having a target of 90% of her annual base salary based on achievement of performance goals set by the Company's Board of Directors or committee thereof (the "Board"), in their sole discretion, and further subject to her continued employment through the payment date. &#8239;Ms. Cordova is generally eligible to participate in Company&#8217;s 2024 Omnibus Incentive Plan as determined by the Board. Further, Ms. Cordova is eligible to participate in the employee benefits generally provided to similarly-situated executive employees, subject to the satisfaction of any eligibility requirements. She will also receive relocation expense reimbursement per the Company&#8217;s policy from the U.S. to Switzerland and COBRA expense reimbursement for six months for continuation of her family's health insurance benefits covering the transition from the U.S. to Swiss healthcare payment systems (in each case grossed up for taxes). Upon termination of Ms. Cordova&#8217;s employment by the Company without cause (but for reasons other than death or disability) or resignation by Ms. Cordova for good reason (each as defined in the Cordova Employment Agreement, a &#8220;Qualifying Termination&#8221;) prior to a change in control, subject to Ms. Cordova&#8217;s execution without revocation of a release of claims, she will be eligible to receive a lump sum payment equal to 100% of her annual base salary. Upon a Qualifying Termination within 12 months following a change in control, and subject to Ms. Cordova&#8217;s execution without revocation of a release of claims, Ms. Cordova will be eligible to&#8239;receive a lump sum payment equal to the aggregate of 200% of her base salary plus 200% of her target annual bonus.&#8239;Additionally, any stock options or other equity awards held by Ms. Cordova will become fully vested on the date of her termination. Pursuant to the Cordova Employment Agreement, Ms.&#8239;Cordova&#8239;is subject to perpetual non-disparagement covenants, as well as&#8239;confidentiality, non-compete and employee, customer and supplier non-solicit covenants applicable during her employment and for&#8239;12&#8239;months thereafter. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing description of the Cordova Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Cordova Employment Agreement, a copy of which is attached to this report as Exhibit 10.1. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Danziger Senior Advisor Agreement</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Mr. Danziger&#8217;s acceptance of his new position as Senior Advisor, on December 11, 2024, Mr. Danziger entered into a new employment agreement with a subsidiary of the Company (the &#8220;Danziger Employment Agreement&#8221;), effective January 1, 2025, to replace his existing employment agreement, dated as of October 10, 2016.&#8239;Under the Danziger Employment Agreement, Mr. Danziger&#8217;s employment is &#8220;at-will&#8221; and may be terminated by either Mr. Danziger or the Company at any time, subject to the Company's obligation to provide severance in certain instances as discussed below. The Danziger Employment Agreement terminates at the close of business on December 31, 2026 (the "End Date"), unless sooner terminated in accordance with his agreement. During the term of his agreement, Mr. Danziger will receive $700,000 per year through December 31, 2025 and $120,000 per year through the End Date (the &#8220;Base Salary&#8221;), and converted from U.S. Dollars to New Israeli Shekels at the exchange rate of 4NIS/$1, subject to adjustment by the Company&#8217;s Compensation Committee of the Board of Directors. Upon termination of Mr. Danziger&#8217;s employment by the Company without &#8220;cause&#8221; (but for reasons other than death or &#8220;disability&#8221;) or resignation by Mr. Danziger for &#8220;good reason&#8221; (each a &#8220;Qualifying Termination&#8221;) within 12 months following a change in control, and subject to Mr. Danziger&#8217;s execution without revocation of a release of claims, Mr. Danziger will be eligible to receive an amount equal to the sum of two times his Base Salary times a fraction equal to the number of days remaining from the date of the Qualifying Termination through the End Date divided by the total number of days of the effective date through the End Date. Additionally, any share options or other equity awards other than Performance Based Restricted Share Units ("PSUs") granted to Mr. Danziger after the effective date of his employment agreement will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">become fully vested on the date of such termination. Pursuant to the Danziger Employment Agreement, Mr.&#8239;Danziger is subject to perpetual confidentiality and non-disparagement covenants, as well as non-compete and employee, customer and supplier non-solicit covenants applicable during his employment and for 12 months thereafter. The foregoing description of the Danziger Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Danziger Employment Agreement, a copy of which is attached to this report as Exhibit 10.2. Mr. Danziger will forfeit certain PSUs upon his resignation from his position as Chief Executive Officer. In connection with his appointment as a Special Advisor, on January 1, 2025, Mr. Danziger will be granted 400,000 Restricted Share Units pursuant to the Company's 2024 Omnibus Incentive Plan ("RSUs") which will vest and convert into the Company's Ordinary Shares in equal installments on December 31, 2025 and December 31, 2026, so long as Mr. Danziger remains an employee of the Company on such dates.</span></div><div><span><br/></span></div><div style="margin-top:10pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Item 9.01     Financial Statements and Exhibits</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Exhibits</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.473%"><tr><td style="width:1.0%"/><td style="width:10.828%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.972%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ceoemploymentagreementex101.htm">Employment Agreement between Ashley Cordova and Novocure GmbH effective as of January 1, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="senioradvisortoceoemployme.htm">Employment Agreement between Asaf Danziger and Novocure (Israel) Ltd. effective as of January 1, 2025</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SIGNATURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">NovoCure Limited</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(Registrant)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">Date: December 11, 2024</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">By: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;text-decoration:underline">/s/ Ashley Cordova       </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">       Name: Ashley Cordova</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">       Title: Chief Financial Officer</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ceoemploymentagreementex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ib6e08ad0a954402c91796815298d1b86_1"></div><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Chief Executive Officer Employment Agreement</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By and between</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novocure GmbH</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, D4 Park 6, 6039 Root D4, Switzerland                  (hereinafter the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;) </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Ashley Cordova, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1550 Liberty Ridge Drive, Suite 115, Wayne PA USA         (hereinafter &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">you</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;) </font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Effective Date&#58; 1 January 2025</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The purpose of this employment agreement (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;) is to set forth and acknowledge the terms of your continued employment with the Novocure Group.  Your formal employment relationship will be with the Company, a Swiss limited liability company and a wholly owned subsidiary of NovoCure Limited, a Jersey (Channel Islands) corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  References herein to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Novocure Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean and refer to, collectively, the Parent, the Company and their respective direct and indirect subsidiaries and affiliates. Upon the date specified above (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), this Agreement will supersede and replace in its entirety all prior employment agreements with any legal entity of the Novocure Group, especially the employment letter agreement between you and Novocure USA LLC, dated as of September 1, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.01pt;text-decoration:underline">Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company shall employ you, and you shall serve the Company, on the terms and conditions set forth in this Agreement.  Your employment with the Company will commence on the Effective Date.  From and after the Effective Date, you will carry out your day-to-day activities hereunder in an office of the Company located in the central Switzerland area. As you are already employed since May 12, 2014 within the Novocure Group, your years of service are recognized under this Agreement.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.01pt;text-decoration:underline">Duties and Responsibilities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">While you are employed by the Company, you will serve as and have the title of Chief Executive Officer of the Novocure Group, under the direction and supervision of the board of directors (or similar governing body) of the Company and the board of directors of the Parent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  You will have such duties and responsibilities that are commensurate with your position and of a similarly-situated executive officer of a similarly-sized public company.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You form part of the Company&#8217;s Executive Management. As such, your working time results from the workload required to fulfil the tasks and functions assigned to you. Any overtime or extra working hours of yours are included in your remuneration according to section 3 below. You are not entitled to additional remuneration in money or compensation in the form of free time for any overtime or extra working hours. If any additional compensation for excess hours or overtime work should ever become due based on any legal provisions, you agree that the Company can deduct such </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">compensation from any discretionary Annual Bonus pursuant to section 3 below or from any other voluntary payment made to you.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">While you are employed by the Company, you will devote your full business time, energy and skill to the performance of your duties and responsibilities hereunder&#59; provided, that nothing in this Agreement shall prevent you from accepting appointment to or continuing to serve on any board of directors or trustees of any non-competing business corporation, charitable organization or other entity with the consent of the Board, which consent shall not be unreasonably withheld.  Notwithstanding the foregoing, you will not engage in any activities that could create an actual or perceived business or fiduciary conflict of interest with the Novocure Group or unreasonably interfere with the conduct of your obligations under this Agreement or any Novocure Group policy or applicable law or regulation (including the laws of any stock exchange on which the shares of Parent stock are listed).</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.01pt;text-decoration:underline">Base Salary and Discretionary Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.71pt">While you are employed by the Company, the Company will pay you a base salary at the rate of CHF 750,000 per year (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;).  Your Base Salary will be paid in accordance with the usual payroll practices of the Company.  While you are employed by the Company, your Base Salary will be reviewed from time to time for possible adjustment by the compensation committee of the Board or its delegate.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.03pt">You will be eligible to receive a discretionary annual cash bonus having a payout at the target level of performance of ninety percent (90%) of your Base Salary (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Target Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;) for each calendar year that you are employed by the Company, payable during the first calendar quarter of the year following the year to which the bonus relates, subject to your continued employment through the payment date.  Such bonus will be subject to your successful achievement of performance goals set by the Board (or committee thereof), in their sole discretion, including, without limitation, goals based on the operating results of the Novocure Group or your individual performance.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.01pt;text-decoration:underline">Equity Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">While you are employed by the Company, you will be eligible to participate in the Parent&#8217;s 2024 Omnibus Incentive Plan or such other equity-based long-term incentive compensation plan, program or arrangement generally made available to similarly situated senior executives of the Company from time to time (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;), as determined in the sole and absolute discretion of the Board or authorized committee thereof.   </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Benefits and Fringes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.71pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except as provided otherwise herein, while you are employed by the Company, you will be entitled to such benefits and fringes, if any, as are generally provided from time to time by the Company to its similarly-situated executive employees, subject to the satisfaction of any eligibility requirements.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.03pt;text-decoration:underline">Vacation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You will be entitled to annual paid vacation in accordance with the Company&#8217;s General Employment Policy Switzerland (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">GEP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) in effect.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.71pt;text-decoration:underline">Reimbursement of Business Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon presentation of appropriate documentation, you will be reimbursed in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time for all reasonable and necessary </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">business expenses incurred in connection with the performance of your duties and responsibilities hereunder.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.03pt;text-decoration:underline">Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You will be eligible for employee benefits, including fringe benefits, and expense reimbursement consistent with the Company&#8217;s policies for similarly situated senior executives in Switzerland.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.71pt;text-decoration:underline">Relocation Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. You will be entitled to reimbursement of your relocation expenses per the Company&#8217;s Global Relocation Policy and as approved by the Board or authorized committee thereof. Provided remain eligible for continuation coverage pursuant to Part 6 of Title I of ERISA (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Company shall pay or reimburse you an amount equal to the full monthly premium for COBRA continuation coverage under the Company&#8217;s medical plan as in effect as of the Effective Date with respect to the level of coverage in effect for your eligible dependents as of such date, on a monthly basis on the first business day of the calendar month next following the calendar month in which the applicable COBRA premiums were paid (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">COBRA Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), with respect to the period from the Effective Date through June 30, 2025, grossed up for any income taxes payable thereon.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Termination of Employment &#47; Probation Period.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.71pt">In deviation of the GEP, the parties agree that there is no probation period and your notice period is six (6) months effective as per end of a calendar month (the &#8220;Notice Period&#8221;). The employment with the Company may be terminated by the Company at any time with or without Cause (as defined below) or by you at any time with or without Good Reason (as defined below).  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a determination by the Board that any of the following have occurred&#58;  (i) your failure to follow the lawful and reasonable directives of the Company or the Board&#59; (ii) your material violation of any material Company policy, including any provision of a Code of Conduct or Code of Ethics adopted by the Company&#59; (iii) your commission of any act of fraud, embezzlement, dishonesty or any other willful or gross misconduct that in the reasonable judgment of the Board has caused or is reasonably expected to result in material injury to the Company&#59; (iv) your unauthorized use or disclosure of any proprietary information or trade secrets of any member of the Novocure Group or any other party to whom you owe an obligation of nondisclosure as a result of your relationship with the Company that in the reasonable judgment of the Board has caused or is reasonably expected to result in material injury to the Company&#59; (v) your conviction of, or plea of guilty or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (or functional equivalent) to, a felony or misdemeanor (other than a minor traffic offense)&#59; or (vi) your material breach of any of your obligations under this Agreement or any written agreement between you and any member of the Novocure Group.  Except for any such event or condition which, by its nature, cannot reasonably be expected to be cured, with respect to the events or conditions described in clauses (i), (ii) or (vi), you shall have thirty (30) days after receipt of written notice from the Company specifying the events or conditions constituting Cause in reasonable detail within which to cure any events or conditions constituting Cause, provided that the Company serves notice of such events or conditions and intended termination within sixty (60) days of the occurrence thereof, and such Cause shall not exist unless either you are not entitled to notice under this sentence, or, if you are entitled to such notice, you fail to cure such acts constituting Cause within such thirty (30)-</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">day cure period.  Termination of your employment shall not be deemed to be for Cause unless, prior to termination, the Company delivers to you copies of resolutions duly adopted by the affirmative vote of not less than a majority of the Board (after reasonable written notice is provided to you and you are given a reasonable opportunity, together with counsel, to be heard before the Board), finding that you have engaged in the conduct described in any of (i)-(vi) above.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.03pt">Subject to Sections 6(c) and 6(d), upon termination of your employment for any reason, the Company will have no obligations under this Agreement other than to pay or provide you&#58;  (w) any unpaid Base Salary during the Notice Period in regular installments in accordance with the Company&#8217;s payroll practices (&#8220;Notice Pay&#8221;)&#59; (x) payment in respect of your earned but unused vacation time through the date of termination (but not in excess of one year&#8217;s vacation time, ignoring any vacation carried over from prior years &#8211; subject to a compensation through garden leave) in a lump sum in cash within 30 days after the date of termination&#59; (y) reimbursement for any unreimbursed expenses reasonably incurred consistent with Novocure Group policies then in effect through the date of termination, in a lump sum in cash within 30 days after the date of termination&#59; and (z) benefits in accordance with the terms of the applicable plans and programs of the Company (collectively, including the timing of payment or provision, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Accrued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.71pt">In addition to the Accrued Benefits, upon a termination of your employment by (i) the Company other than (A) for Cause or (B) as a result of your death or Disability (as defined in the Plan) or (ii) you for Good Reason (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Qualifying Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), then, except as otherwise set forth in Section 6(d) below, and subject to your timely execution and delivery to the Company of a release of claims in substantially the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#34;) within twenty-one (21) days, or if required by law, forty-five (45) days, following the date of the Qualifying Termination, and the expiration of the seven (7)-day right of revocation with respect to the Release, the Company shall provide you with an aggregate lump sum payment payable at the end of the Notice Period equal to&#58; (x) one hundred percent (100%) of your annual Base Salary at the level in effect as of the date of the Qualifying Termination minus (y) the amounts you receive as salary during the Notice Period, which will be paid in in accordance with the Company&#8217;s payroll practices during the Notice Period (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (it being understood that it is the intent of the parties that the amount payable pursuant to this Section 6(c) plus the Notice Payments shall equal one hundred (100%) of your annual Base Salary. The payments described in this Section 6(c) will be paid or provided (or begin to be paid or provided) as soon as administratively practicable after the Release becomes irrevocable (and any amount which would have otherwise been paid prior to such date paid in a lump sum at such time, and any remaining payments on the schedule described above).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.03pt">In addition to the Accrued Benefits, upon a Qualifying Termination within twelve (12) months following a Change in Control (as defined in the Plan), then, in lieu of the payments and benefits under Section 6(c) above, and subject to your timely execution and non-revocation of the Release within twenty-one (21) days, or if required by law, forty-five (45) days, following the date of such Qualifying Termination, and the expiration of the seven (7)-day right of revocation with respect to the Release, the Company shall provide you with the following&#58; (I) an aggregate lump sum payment payable at the end of the Notice </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Period equal to&#58; (x) two hundred percent (200%) of the sum of your annual Base Salary and your Target Bonus at the levels in effect as of the date of the Qualifying Termination minus (y) all Notice Payments (it being understood that it is the intent of the parties that the amount payable pursuant to this Section 6(d) plus the Notice Payments shall equal two hundred percent (200%) of the sum of your annual Base Salary and your Target Bonus&#59; and (II) all stock options or other equity or equity-based awards held by you that have not previously become vested and (if applicable) exercisable as of the date of the Qualifying Termination shall, upon such termination, become immediately and fully vested and exercisable, without regard to the terms of any applicable award agreement or plan document, and such awards shall otherwise continue to apply on the same terms.  The payments described in this Section 6(d) will be paid or provided (or begin to be paid or provided) as soon as administratively practicable after the Release becomes irrevocable (and any amount which would have otherwise been paid prior to such date paid in a lump sum at such time, and any remaining payments on the schedule described above).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.71pt">For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean that you have complied with the &#8220;Good Reason Process&#8221; following the occurrence of any of the following events&#58;  (i) the Company&#8217;s material failure to make any required payment to you hereunder&#59; (ii) the substantial diminution of your position, reporting relationship, duties or responsibilities through no fault of your own&#59; (iii) a reduction in your Base Salary or Target Bonus of more than ten percent (10%), unless such reduction is applied to all senior executives&#59; (iv) a requirement that you move your principal business location to one that would increase your commute by more than thirty (30) miles from the Company&#8217;s location in effect on the Effective Date&#59; or (v) the Company&#8217;s willful breach of any of its material obligations under any written agreement with you.  For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason Process</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean that (a) you notify the Company and the Board in writing of the occurrence of the alleged Good Reason condition within sixty (60) days of you becoming aware of the occurrence of such condition&#59; (b) the Company shall have a period of not less than thirty (30) days following such notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to remedy the alleged condition, during which time you cooperate in good faith with the Company&#8217;s efforts to remedy the condition&#59; (c) the alleged Good Reason condition is not remedied during the Cure Period&#59; and (d) you terminate your employment within sixty (60) days after the end of the Cure Period.  If the Company cures the alleged Good Reason condition during the Cure Period in your reasonable good faith judgment, Good Reason shall be deemed not to have occurred.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:9pt;text-decoration:underline">Covenants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.71pt;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">So long as you are employed by the Company under this Agreement and for the twelve (12)-month period following the termination of your employment with the Company for any reason (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), you agree that you will not, directly or indirectly, without the prior written consent of the Company, engage in Competition worldwide with the Novocure Group.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means participating, directly or indirectly, as an individual proprietor, partner, stockholder, officer, employee, director, joint venturer, investor, lender, consultant or in any other capacity whatsoever in any business or in the development of any business if (A) such business competes or would compete with the business of the Novocure Group (it being understood that the business of the Novocure Group is the development and commercialization of its proprietary tumor </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">treating fields (TTF) therapy for the treatment of solid tumor cancers (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)) and (B) your activities related to such business would create the opportunity for you to use confidential and proprietary information of the Novocure Group in connection with any other product being developed, manufactured, supplied or sold by any such business or business under development that competes with or upon introduction of a product would compete with the Business.  For the avoidance of doubt and by way of example, the foregoing restrictions would not preclude you from being employed by a pharmaceutical company during the Restricted Period to the extent that your activities at such pharmaceutical company would not be directly related to the development, marketing or sale of products that are directly competitive with the Business.  Notwithstanding the foregoing, nothing contained in this Section 7(a) shall prohibit you from (i) investing, as a passive investor, in any publicly held company provided that your beneficial ownership of any class of such publicly held company&#8217;s securities does not exceed one percent (1%) of the outstanding securities of such class, or (ii) with the consent of the Board, entering the employ of any academic institution or governmental or regulatory instrumentality of any country or any domestic or foreign state, county, city or political subdivision.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.03pt;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You agree that you will not, directly or indirectly, use, make available, sell, disclose or otherwise communicate to any person or entity, other than in the course of your assigned duties hereunder and for the benefit of the Novocure Group, either while you are employed by the Company hereunder or at any time thereafter, any business and technical information or trade secrets, nonpublic, proprietary or confidential information, knowledge or data relating to the Novocure Group, whether the foregoing will have been obtained by you during your employment or otherwise.  The foregoing will not apply to information that (i) was known to the public prior to its disclosure to you&#59; (ii) becomes generally known to the public or in the industry subsequent to disclosure to you through no wrongful act by you or any of your representatives&#59; or (iii) you are required to disclose by applicable law, regulation or legal process (provided that you provide the Company with prior notice of the contemplated disclosure and cooperate with the Company in seeking a protective order or other appropriate protection of such information).  Notwithstanding the foregoing or any other provision in this Agreement or otherwise, nothing herein shall prohibit you from reporting possible violations of federal or state law or regulation to any governmental agency or entity or self-regulatory organization including but not limited to the Department of Justice, the Securities and Exchange Commission, Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of federal or state law or regulation (it being understood that you do not need the Company&#8217;s prior authorization to make any such reports or disclosures and you are not required to notify the Company that you have made such reports or disclosures).  </font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.71pt;text-decoration:underline">Non-Solicitation of Customers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You agree that during the Restricted Period, you will not, directly or indirectly, solicit or influence, or attempt to solicit or influence, customers of the Novocure Group to purchase goods or services then sold by the Novocure Group from any other person or entity.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.03pt;text-decoration:underline">Non-Solicitation of Suppliers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You agree that during the Restricted Period, you will not, directly or indirectly, solicit or influence, or attempt to solicit or influence, the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Novocure Group&#8217;s suppliers to provide goods or services then provided to the Novocure Group to any other person or entity in Competition with the Novocure Group.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.71pt;text-decoration:underline">Non-Solicitation of Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You recognize that you will possess confidential information about other employees of the Novocure Group relating to their education, experience, skills, abilities, compensation and benefits, and inter-personal relationships with customers of the Novocure Group.  You recognize that the information you possess and will possess about these other employees is not generally known, is of substantial value to the Novocure Group in developing its business and in securing and retaining customers, and has been and will be acquired by you because of your business position with the Novocure Group.  You agree that, during the Restricted Period, you will not (x) directly or indirectly, individually or on behalf of any other person or entity solicit or recruit any employee of the Novocure Group to leave such employment for the purpose of being employed by, or rendering services to, you or any person or entity unaffiliated with the Novocure Group, or (y) convey any such confidential information or trade secrets about other employees of the Novocure Group to any person or entity other than in the course of your assigned duties hereunder and for the benefit of the Novocure Group or as otherwise required by law or judicial or administrative process.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.04pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You and the Novocure Group agree that neither will, nor induce others to, Disparage the Novocure Group or any of their past or present officers, directors, employees or products, or you.  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Disparage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; will mean you or any Novocure Group officer or director making comments or statements to the press, the Novocure Group&#8217;s employees or any individual or entity with whom the Novocure Group has a business relationship, or any prospective new employer of yours, that would adversely affect in any manner&#58;  (i) the conduct of the business of the Novocure Group (including, without limitation, any products or business plans or prospects)&#59; or (ii) the business reputation of the Novocure Group, or any of its products, or its past or present officers, directors, employees, stockholders and affiliates, or you.  Nothing in this Section 7(f) shall prevent you or representatives of the Novocure Group from (x) pleading or testifying, to the extent that he or she reasonably believes such pleadings or testimony to be true, in any legal or administrative proceeding if such testimony is compelled or requested, (y) from otherwise complying with legal requirements, or (z) your making any truthful and normal competitive comments and statements that do not violate Section 7 of this Agreement or, directly or indirectly, mention the Novocure Group or any of its executives or officers and are not directed at customers or employees of the Novocure Group.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.03pt;text-decoration:underline">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-29.31pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">You acknowledge and agree that all trade secrets, works, concepts, drawings, materials, documentation, procedures, diagrams, specifications, models, processes, formulae, data, programs, knowhow, designs, techniques, ideas, methods, inventions, discoveries, improvements, work products or developments or other works of authorship (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), whether patentable or unpatentable, (x) that relate to your work with the Company or any other member of the Novocure Group, made, developed or conceived by you, solely or jointly with others or with the use of any of the Novocure Group&#8217;s equipment, supplies, facilities or trade secrets or (y) suggested by </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">any work that you perform in connection with the Novocure Group, either while performing your duties with the Novocure Group or on your own time, but only insofar as the Inventions are related to your work as an employee of the Company or the Novocure Group, belong exclusively to the Company (or its designee and assigns, including without limitation the Parent), whether or not patent applications are filed thereon.  You acknowledge and agree that you have previously disclosed to the Company all Inventions that belong to the Company pursuant to the previous sentence and that you have kept and will keep full and complete written records (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), in the manner prescribed by the Company, of all Inventions, and will promptly disclose all future Inventions completely and in writing to the Company.  The Records are and will be the sole and exclusive property of the Company (or its designee and assigns, including without limitation the Parent), and you will surrender them upon the termination of your employment, or upon the Company&#8217;s request.  You do hereby assign to the Company (and its designees and assigns) the Inventions, including all rights in and to patents and other intellectual property rights that may issue thereon in any and all countries, whether during your past employment with the Company or subsequent to the term of this Agreement, together with the right to file, in your name or in the name of the Company (or its designee), applications for patents and equivalent rights (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Applications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  You will, at any time during and subsequent to the term of this Agreement, make such Applications, sign such papers, take all rightful oaths, and perform all acts as may be requested from time to time by the Company with respect to the Inventions and the underlying intellectual property.  You will also execute assignments to the Company (or its designee or assigns) of the Applications, and give the Company and its attorneys all reasonable assistance (including the giving of testimony) to obtain the Inventions and the underlying intellectual property for its benefit, all without additional compensation to you from the Company, but entirely at the Company&#8217;s expense.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-32.64pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">In addition, the Inventions are deemed &#8220;work made for hire,&#8221; as such term is defined under the copyright law of the United States, on behalf of the Company and you agree that the Company (or its designees or assigns) is and will be the sole owner of the Inventions, and all underlying rights therein, in all media now known or hereinafter devised, throughout the universe and in perpetuity without any further obligations or compensation to you.  If the Inventions, or any portion thereof, are deemed not to be &#8220;work made for hire,&#8221; you hereby irrevocably convey, transfer, assign and deliver to the Company (or its designees or assigns), all rights, titles and interests in all media now known or hereinafter devised, throughout the universe and in perpetuity, in and to the Inventions and the underlying intellectual property, including without limitation, (A) all of your rights, titles and interests in the copyrights (and all renewals, revivals and extensions thereof) related to the Inventions and the underlying intellectual property&#59; (B) all rights of any kind or any nature now or hereafter recognized, including without limitation, the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">unrestricted right to make modifications, adaptations and revisions to the Inventions, to exploit and allow others to exploit the Inventions and the underlying intellectual property&#59; and (C) all rights to sue at law or in equity for any infringement, or other unauthorized use or conduct in derogation of the Inventions, known or unknown, prior to the date hereof, including without limitation the right to receive all proceeds and damages therefrom.  In addition, you hereby waive any so-called &#8220;moral rights&#8221; with respect to the Inventions.  You hereby waive any and all currently existing and future monetary rights in and to the Inventions and all patents and other intellectual property rights that may issue thereon, including, without limitation, any rights that would otherwise accrue to your benefit by virtue of you being an employee of or other service provider to the Company.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-35.97pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">To the extent that you are unable to assign any of your right, title or interest in any Invention under applicable law, for any such Invention and the underlying intellectual property rights, you hereby grant to the Company (or its designees or assigns) an exclusive, irrevocable, perpetual, transferable, worldwide, fully paid license to such Invention and the underlying intellectual property, with the right to sublicense, use, modify, create derivative works and otherwise fully exploit such Invention and the underlying intellectual property, to assign this license and to exercise all rights and incidents of ownership of the Invention.</font></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-35.31pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:18pt">To the extent that any of the Inventions are derived by, or require use by the Company of, any works, Inventions, or other intellectual property rights that you own, which are not assigned hereby, you hereby grant to the Company an irrevocable, perpetual, transferable, worldwide, non-exclusive, royalty free license, with the right to sublicense, use, modify and create derivative works using such works, Inventions or other intellectual property rights, but only to the extent necessary to permit the Company (or its designees or assigns) to fully realize their ownership rights in the Inventions.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.03pt;text-decoration:underline">Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Upon the receipt of notice from the Company (including outside counsel), you agree that while employed by the Company or any member of the Novocure Group and for a reasonable period thereafter, you will respond and provide information with regard to matters in which you have knowledge as a result of your employment with the Company, and will provide reasonable assistance to the Novocure Group and its representatives in defense of any claims that may be made against the Novocure Group, and will assist the Novocure Group in the prosecution of any claims that may be made by the Novocure Group, to the extent that such claims may relate to the period of your employment with the Company (or any predecessor) and were within your knowledge.  You agree to promptly inform the Company if you become aware of any lawsuits involving such claims that may be filed or threatened against the Novocure Group.  You also agree to promptly inform the Company (to the extent you are legally permitted to do so) if you are asked to assist in any investigation of the Novocure Group (or their actions), regardless of whether a lawsuit or other proceeding has then been filed against the Novocure Group with respect to such investigation, and will not do so unless legally required.  Subject to any customary and </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reasonable limitations as may be set forth in any other written agreement between you and any member of the Novocure Group, the Company will reimburse you for pre-approved out-of-pocket expenses incurred in connection with such cooperation.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.7pt;text-decoration:underline">Return of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On the date of the termination of your employment with the Company for any reason (or at any time prior thereto at the Company&#8217;s request), you will return all property belonging to the Novocure Group (including, but not limited to, any Novocure Group provided laptops, computers, mobile&#47;smart phones, security cards&#47;fobs, or other equipment, or documents and property belonging to the Novocure Group, but not your personal rolodex to the extent it contains only contact information).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:24.7pt;text-decoration:underline">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It is further expressly agreed that the Company will or would suffer irreparable injury if you were to violate the provisions of this Section 7 and that the Novocure Group would by reason of such violation be entitled to injunctive relief in a court of appropriate jurisdiction and you further consent and stipulate to the entry of such injunctive relief in such court prohibiting you from violating the provisions of this Section 7.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.03pt;text-decoration:underline">Survival of Provisions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The obligations contained in this Section 7 will survive the termination of your employment with the Company or any member of the Novocure Group and will be fully enforceable thereafter.  If it is determined by a court of competent jurisdiction in any state that any restriction in this Section 7 is excessive in duration or scope or extends for too long a period of time or over too great a range of activities or in too broad a geographic area or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by the law of that state or jurisdiction.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.01pt;text-decoration:underline">Representation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You represent and warrant that your execution and delivery of this Agreement and your performing the contemplated services does not and will not conflict with or result in any breach or default under any agreement, contract or arrangement which you are a party to or violate any other legal restriction, nor will any member of the Novocure Group knowingly request or require you to take any action that would violate any prior agreement, contract or arrangement of which the Company has been made aware on or prior to the date of this Agreement.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:27.01pt;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Notwithstanding anything else herein, this Agreement is personal to you and neither the Agreement nor any rights hereunder may be assigned by you.  The Company may assign the Agreement to an affiliate or to any acquiror of all or substantially all of the assets of the Company or otherwise to any person in connection with a Change in Control.  This Agreement will inure to the benefit of and be binding upon the personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees, legatees and permitted assignees of the parties.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.01pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement will be governed by, and construed under and in accordance with, the internal laws of Switzerland, without reference to rules relating to conflicts of laws. The Company and you each irrevocably submit to the jurisdiction of the competent courts located in Zug, Switzerland and hereby waive any objection regarding jurisdiction or forum.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.01pt;text-decoration:underline">Entire Agreement&#59; Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement and the agreements referenced herein contain the entire agreement of the parties relating to the subject matter hereof, and supersede in their entirety any and all prior agreements, understandings or representations relating to the subject </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">matter hereof.  No amendments, alterations or modifications of this Agreement will be valid unless made in writing and signed by the parties hereto.  To the extent implied herein, the applicable provisions of this Agreement shall survive any termination of your employment. </font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.01pt;text-decoration:underline">Applicable Policies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The current English version of the GEP is applicable and forms an integral part of this Employment Contract. In case of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">conflicts with the terms and conditions of this Agreement, the terms and conditions of this Agreement shall prevail unless otherwise specifically set forth in this Agreement.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Furthermore, you have to comply with any instructions and regulations, in particular the Expense Reimbursement Policy and the Notice of Fair Processing of Employee Data, issued by the Company and&#47;or by the Novocure Group from time to time.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:22.26pt;text-decoration:underline">Section Headings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The section h</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">eadings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> used in this Agreement are included solely for convenience and will not affect, or be used in connection with, the interpretation of this Agreement.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.01pt;text-decoration:underline">Severability&#59; Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The provisions of this Agreement will be deemed severable and the invalidity of unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof.  No failure to exercise, delay in exercising, or single or partial exercise of any right, power or remedy by either party, and no course of dealing between the parties, shall constitute a waiver of, or shall preclude any other or further exercise of, any right, power or remedy.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.01pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement may be executed in several counterparts (including via facsimile), each of which will be deemed to be an original but all of which together will constitute one and the same instruments.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.01pt;text-decoration:underline">Compensation Recovery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Any amounts paid pursuant to this Agreement shall be subject to recoupment in accordance with any clawback policy that Parent and&#47;or the Company has adopted, adopts or is otherwise required by law to adopt, whether pursuant to the listing standards of any national securities exchange or association on which the Parent&#8217;s securities are listed, the Dodd-Frank Wall Street Reform and Consumer Protection Act and&#47;or other applicable law.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.01pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All notices, consents or other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given when delivered personally or one business day after being sent by a nationally recognized overnight delivery service, charges prepaid.  Notices also may be given by facsimile or electronically via PDF and shall be effective on the date transmitted if confirmed within 48 hours thereafter by a signed original sent in the manner provided in the preceding sentence.  Notice to you shall be sent to your most recent address on file with the Company.  Notice to the Company shall be sent to its address set forth on the first page hereto.  Either party may change its address for notice and the address to which copies must be sent by giving notice of the new addresses to the other party in accordance with this Section 18, provided, however, that any such change of address notice shall not be effective unless and until received.</font></div><div style="margin-bottom:6pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;padding-left:21.01pt;text-decoration:underline">Indemnification&#59; Directors and Officers Liability Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In addition to any rights to indemnification to which you may be entitled under the Company&#8217;s and&#47;or Parent&#8217;s governing documents or other agreement, the Company and&#47;or Parent (as applicable) shall indemnify you at all times during and after your employment terminates for any reason to the maximum extent permitted under applicable law, including its provisions regarding advancement of costs and attorneys&#8217; fees, in connection with any action, suit, investigation or proceeding based in whole or in part upon your </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">actions, inaction, or status as an employee, officer, or director of any member of the Novocure Group, except to the extent it is finally determined by a court of competent jurisdiction that you are either not entitled to indemnification hereunder or otherwise or that any such action or inaction by you that gave rise to any such action, suit, investigation or proceeding arose out of your own gross negligence, willful misconduct or fraud.  The Company and&#47;or Parent shall maintain directors and officers liability insurance in commercially reasonable amounts (as reasonably determined by the Board or the Parent Board (as applicable), and you shall be covered under such insurance to the same extent as any other senior executives of the Company and&#47;or the Novocure Group, both during employment and thereafter while potential liability exists.</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Remainder of page intentionally blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We hope that you find the foregoing terms and conditions acceptable.  You may indicate your agreement with the terms and conditions set forth in this Agreement by signing the enclosed duplicate original of this Agreement and returning it to me.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">We look forward to your employment with the Company.</font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Novocure GmbH</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  _______________________</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> </font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;   </font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;  </font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58;  December 11, 2024</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Accepted and Agreed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Ashley Cordova&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Ashley Cordova </font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58; December 11, 2024</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;padding-left:54pt;padding-right:54pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EXHIBIT A </font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RELEASE AGREEMENT</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This RELEASE AGREEMENT (&#8220;Agreement&#8221;) made &#91;          &#93;, &#91;    &#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), between &#91;COMPANY&#93; (including its successors and assigns, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and &#91;FIRST_NAME&#93; &#91;LAST_NAME&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Executive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Termination Date.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Executive&#8217;s employment with the Company terminates with effect on &#91;INSERT DATE&#93; (the &#34;Termination Date&#34;). For the avoidance of doubt, the Termination Date is not subject to any deferment for whatever reason, including, but not limited to, sickness or accident.</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In consideration of the amounts to be paid by the Company pursuant to the employment agreement, dated as of January 1, 2025 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Employment Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),  Executive, on behalf of himself and his heirs, executors, devisees, successors and assigns, knowingly and voluntarily releases, remises, and forever discharges the Company and its parent company, subsidiaries and affiliates, together with each of their current and former principals, officers, directors, shareholders, agents, representatives and employees, and each of their heirs, executors, successors and assigns (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Releasees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), from any and all debts, demands, actions, causes of action, accounts, covenants, contracts, agreements, claims, damages, omissions, promises, and any and all claims and liabilities whatsoever, of every name and nature, known or unknown, suspected or unsuspected, both in law and equity (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), which Executive ever had, now has, or may hereafter claim to have against the Releasees by reason of any matter or cause whatsoever arising from the beginning of time to the time he signs this Agreement arising out of his employment by, or termination from employment by, the Company or the Novocure Group (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">General Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  References herein to the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Novocure Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean and refer to, collectively, the Company, Novocure Limited, a Jersey (Channel Islands) corporation, and their respective direct and indirect subsidiaries and affiliates.  This General Release of Claims shall apply to any Claim of any type, related to or arising out of Executive&#8217;s employment relationship, or the termination of his employment, with the Company.</font></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">For the purpose of implementing a full and complete release, Executive understands and agrees that this Agreement is intended to include all claims, if any, which Executive or his heirs, executors, devisees, successors and assigns may have and which Executive does not now know or suspect to exist in his favor against the Releasees, from the beginning of time until the time he signs this Agreement, and this Agreement extinguishes those claims.</font></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">In consideration of the promises of the Company set forth in the Employment Agreement, Executive hereby releases and discharges the Releasees from any and all Claims that Executive may have against the Company.   Executive also understands that, by signing this Agreement, he is waiving all Claims against any and all of the Releasees.</font></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.02pt">Except as provided in Section 6 of the Employment Agreement, Executive acknowledges and agrees that the Company has fully satisfied any and all obligations owed to him arising out of his employment with or termination from the Company, and no further sums or benefits are owed to him by the Company or by any of the other Releasees at any time.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:22.7pt">This General Release does not waive any right Executive may have (i) to accrued and vested benefits or benefits otherwise due (other than severance, termination or change in control benefits) under any employee benefit plan of the Company or (ii) to coverage and&#47;or indemnification by the Company pursuant to any directors&#8217; and officers&#8217; liability insurance coverage of the Company or pursuant to the organizational or governance documents of the Company.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Consultation with Attorney&#59; Voluntary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company advises Executive to consult with an attorney of his choosing prior to signing this Agreement.  Executive understands and agrees that he has the right and has been given the opportunity to review this Agreement and, specifically, the General Release in Section 1 above, with an attorney.  Executive also understands and agrees that he is under no obligation to consent to the General Release set forth in Section 1 above.  Executive acknowledges and agrees that the payments to be made to Executive pursuant to the Employment Agreement are sufficient consideration to require him to abide with his obligations under this Agreement, including but not limited to the General Release set forth in Section 1.  Executive represents that he has read this Agreement, including the General Release set forth in Section 1, and understands its terms and that he enters into this Agreement freely, voluntarily, and without coercion.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Effective Date&#59; Revocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Executive acknowledges and represents that he has been given &#91;twenty-one (21)&#47;forty-five (45)&#93;</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;1&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> days during which to review and consider the provisions of this Agreement and, specifically, the General Release set forth in Section 1 above.  Executive further acknowledges and represents that he has been advised by the Company that he has the right to revoke this Agreement for a period of seven (7) days after signing it.  Executive acknowledges and agrees that, if he wishes to revoke this Agreement, he must do so in a writing, signed by him and received by the Company no later than 5&#58;00 p.m. Eastern Time on the seventh (7th) day of the revocation period.  If no such revocation occurs, the General Release and this Agreement shall become effective on the eighth (8th) day following his execution of this Agreement.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  In the event that any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remainder of the Agreement shall not in any way be affected or impaired thereby.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and any other document or instrument delivered pursuant hereto, and all claims or causes of action that may be based upon, arise out of or relate to this Agreement will be governed by, and construed under and in accordance with, the internal laws of Switzerland, without reference to rules relating to conflicts of laws.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Possible Continuation of Insurance Coverage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Executive remains insured under the Company's existing insurance coverage until the Termination Date or, if earlier, until taking up substitute employment in Switzerland, at the same terms as applicable at the date of execution of this Agreement.</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Executive confirms having been informed by the Company of the possibility to maintain, for his own account, his previous insurance coverage by entering into private arrangements with the Company's insurance providers, according to the terms of the Company's insurance policies (if any).</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.1</font></div></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Letter of Reference.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> On the Termination Date, the Company shall provide the Executive with a final letter of reference. Upon request, the Company shall provide the Executive with an interim reference letter at an earlier date.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:9pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement, the Employment Agreement and the other agreements referred to in the Employment Agreement constitute the entire agreement and understanding of the parties with respect to the subject matter herein and supersedes all prior agreements, arrangements and understandings, written or oral, between the parties.  Executive acknowledges and agrees that he is not relying on any representations or promises by any representative of the Company concerning the meaning of any aspect of this Agreement.</font></div><div style="margin-bottom:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:3pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.</font></div><div style="margin-bottom:6pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the dates set forth below.</font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOVOCURE GMBH</font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">                                                                  </font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; </font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div><div style="margin-bottom:6pt;text-indent:216pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:216pt"><font><br></font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">                                                                  </font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58; Ashley Cordova </font></div><div style="margin-bottom:6pt;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58;</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;1&#93;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Consideration period to be determined at time of termination. </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>senioradvisortoceoemployme.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i917e4accb51d486491a2fe2fb863a4a4_1"></div><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">AMENDED AND RESTATED EMPLOYMENT AGREEMENT</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This Amended and Restated Employment Agreement (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) is entered into in Tel-Aviv, Israel effective as of January 1, 2025 (hereinafter, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), by and between Novocure (Israel) Ltd., of Topaz Building, 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> floor, MATAM Center, Sha&#8217;ar Ha&#8217;Carmel, P.O. Box 15022, Haifa 3190500, a company incorporated under the laws of the State of Israel (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Asaf Danziger</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the Company is a wholly-owned subsidiary (indirectly) of Novocure Limited, a Jersey (Channel Islands) corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;)&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the Employee and the Company are party to that certain Employment Agreement, dated as of October 10, 2016, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Prior Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), pursuant to which the Employee serves as the President of the Company and Chief Executive Officer of Parent&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, on September 3, 2024, Employee resigned his positions with respect to the Company and Parent, effective at the close of business on December 31, 2024&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> the Employee and the Company desire to amend and restate the Prior Agreement as of the Effective Date pursuant to the terms hereof, in order to assure the Company, the Parent and their respective direct and indirect subsidiaries and affiliates (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Novocure Group</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) of the Employee&#8217;s continued employment in a new non-executive officer capacity and to compensate him therefor and the Employee is willing to continue to be so employed.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">, in consideration of the mutual promises contained herein, and intending to be legally bound, the parties hereto hereby declare and agree as follows&#58;</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Employment and Duties</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.8pt;text-decoration:underline">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Upon the terms and subject to the conditions set forth in this Agreement, the Company hereby agrees to continue to employ the Employee, and the Employee hereby agrees to serve, as the Senior Advisor to the Chief Executive Officer of Parent. In such capacity, until January 1, 2026, the Employee agrees to devote Employee&#8217;s full business time to the business of the Company and the Novocure Group, and to perform the duties commensurate with his position as Senior Advisor, under the direction and supervision of the Chief Executive Officer of the Parent and board of directors (or similar governing body) of the Company and the board of directors of the Parent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), and to use his best efforts, skill and energy to promote and serve the interests of the Company and the other members of the Novocure Group. From January 1, 2026 through the End Date (as defined below), Employee agrees to devote his time on a part-time (approximately 25%) basis to the business of the Company and the Novocure Group and nothing in this Agreement other than the provisions of Section 5 hereof shall prevent Employee from accepting other part-time employment or consultancy, or appointment to or continuing to serve on any board of directors or trustees of any non-competing business corporation, charitable organization or other entity. The Employee&#8217;s regular place of employment shall be in Israel, and will include travel and period of stay abroad according to the requirement of his position with the Company. While the Employee&#8217;s formal employment relationship will be with the Company, the Employee agrees to serve in such other positions, including without limitation, on such boards of directors (or </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">similar governing bodies) or committees thereof, as may be mutually agreed upon by the Employee and the Novocure Group. Employee agrees that in lieu of any compensation and benefits (including any rights to termination pay, equity grants, accelerated vesting and bonuses) payable under the Prior Agreement from and after the Effective Date until his later termination of employment with the Novocure Group for any reason, he agrees that he is only entitled to the compensation set forth in this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.02pt;text-decoration:underline">Position of Trust</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Employee is being employed in a management position, within the meaning of the Hours of Work and Rest Law, 5711-1951, which requires a special measure of personal trust as defined thereunder. Therefore, the provisions of such law shall not apply to the Employee, and he shall not be entitled to any compensation for his employment beyond that specified in this Agreement. The Employee shall not engage in any activities that may interfere or conflict with the proper discharge of his duties hereunder, and shall immediately notify the Chief Executive Officer of any actual or potential business or fiduciary conflict of interest that may arise with respect to his employment&#59; provided, that subject to the foregoing notification obligation, the Employee shall be permitted to (x) accept appointment to or continue to serve on any board of directors or trustees of any business corporation, charitable organization or other entity with the consent of the Board and (y) manage his passive personal investments.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9pt;text-decoration:underline">Compensation and Other Benefits</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-0.01pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The Company shall pay and provide the following compensation and other benefits to the Employee during the Term (as defined below) as compensation for all services rendered hereunder&#58;</font></div><div style="padding-left:36pt;text-indent:-0.01pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.7pt;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. For the period from the Effective date through December 31, 2025, the Company shall pay to the Employee a gross, monthly base salary of US $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">58,333.33</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">, and thereafter, a gross, monthly base salary of US $</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">10,000</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> payable in accordance with the payroll practices of the Company in a manner consistent with past practices (hereinafter the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Base Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;). The Base Salary shall be converted from US Dollars to Israeli Shekels based on the applicable US Dollar&#47;NIS exchange rate, as determined in accordance with the Company&#8217;s senior executive payroll practices, as determined and fixed from time to time by the Board or compensation committee of the Board, or, if no such determination has been made, on the actual date of payment. For purposes of this Agreement, the US Dollar&#47;NIS exchange rate is set at 1 US Dollar to 4 NIS. While the Employee is employed, the exchange rate shall be reviewed from time to time for possible adjustment by the compensation committee of the Board.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Any and all taxes and liabilities applicable from time to time in connection with the Base Salary, the Employee&#8217;s benefits and&#47;or other payments to which the Employee is entitled to under this Agreement, will be borne by the Employee. The Company shall be entitled to deduct or withhold from the Base Salary, and from all other payments made under this Agreement, all taxes and charges which the Company may be required to deduct or withhold, according to the applicable law. Notwithstanding the foregoing, all tax consequences of the benefits to the Employee in connection with the automobile as set under Section 2(f) below, shall be borne by the Company and the Company shall pay to the Employee, concurrently with the </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">monthly payments of the Base Salary, such amount of income tax as it deems appropriate in connection therewith (without such payments being deemed, for any purpose whatsoever (including without limitation, for the calculation of the severance payment and&#47;or any other social benefit) as a part of Employee&#8217;s Base Salary hereunder).</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline">Discretionary Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Employee shall not be eligible to receive or participate in any discretionary annual cash bonus program sponsored by the Company or Parent&#59; provided, however, that Employee shall be entitled to receive his Target Bonus (as defined in the Prior Agreement) with respect to 2024 and payable in 2025, if and as determined by the Board.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.02pt;text-decoration:underline">Vacation, Relaxation and Sick Leave</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-23.76pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:107%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:18pt">The Employee shall be entitled to twenty-eight (28) days of paid vacation for the period from the Effective Date through December 31, 2025, and seven (7) days of paid vacation for the period from January 1, 2026 through the End Date, to be taken with adequate regard to the needs of the Company.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:18pt;text-decoration:underline">Untaken Vacation Time</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Every twelve (12) months, the Employee may, at his election&#58; (i) subject to applicable law, accumulate the untaken vacation time to which he is entitled until that date, for use in the two subsequent years&#59; or (ii) receive the Base Salary payable with respect to any unused vacation days not taken until that date.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-30.99pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">iii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:18pt;text-decoration:underline">Recuperation Pay</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Employee shall be entitled to recuperation pay (d&#8217;mey havra&#8217;ah) in accordance with the provisions of the applicable law.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-30.33pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">iv.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:18pt;text-decoration:underline">Sick Days</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Employee shall be entitled to one (1) month of sick days (days of absence from work at full compensation due to legitimate illness) per year. Any balance of such sick days not used in any year may be accumulated for use as sick days in subsequent years, up to a maximum of six (6) months. The paid sick days provided for in this paragraph shall come in lieu of any obligations under the Sick Pay Law, 5736-1976.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.7pt;text-decoration:underline">Additional Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Company shall also make each of the following payments on behalf of the Employee&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-23.76pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:107%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:18pt;text-decoration:underline">Advanced Study Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. For each month during the Employee&#8217;s employment, the Company shall contribute an amount equal to 7.5% of the Employee&#8217;s monthly Base Salary (but not exceeding the highest deductible and&#47;or credible amount for tax purposes (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Deductible Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;)), and shall deduct an amount equal to 2.5% of the Employee&#8217;s monthly Base Salary for such month, from the Employee&#8217;s monthly Base Salary, and forward such amount on behalf of the Employee to the an advance study fund designated by the Employee in the name of the Employee, to cover a professional education fund (keren hishtalmut). The difference between 7.5% of the Employee&#8217;s monthly Base Salary and the Deductible Amount shall be monthly paid to the Employee by the Company at the same time with the Base Salary (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Additional Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;). Nevertheless, the parties hereby agree that such Additional Amount shall not be deemed, for any purpose </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">whatsoever, including without limitation for the calculation of the severance payment and&#47;or any other social benefit, as a part of the Employee&#8217;s Base Salary hereunder.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:18pt;text-decoration:underline">Managers&#8217; Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. </font></div><div><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">A. If the Employee has not elected for contributions to be made to the Pension Fund (as defined in and pursuant to subsection (B) below), then (i) the Company shall contribute, on a monthly basis, an amount equal to 8.33% of the Employee&#8217;s Base Salary for such month to a manager&#8217;s insurance policy with an insurance company designated by the Employee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Insurance Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) in the name of the Employee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), to cover severance pay benefits, (ii) the Company shall contribute, on a monthly basis, an amount equal to 6.5% (or any other increased percentage as shall be updated from time to time by the Minister of Economy) of the Employee&#8217;s Base Salary for such month and forward such amount on behalf of the Employee, to the Policy, to cover pension benefits (tagmulim) and (iii) the Employee shall pay, on a monthly basis, an amount equal to 6% (or any other increased percentage as shall be updated from time to time by the Minister of Economy) of the monthly Base Salary as premium on the Policy, and such amount shall be deducted by the Company from the Base Salary and transferred to the Insurance Company. </font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">In addition, the Company shall contribute, on a monthly basis, an amount of up to 2.5% of the Employee&#8217;s Base Salary for such month, to the Policy, to cover a work disability plan.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">B. In lieu of the contributions made in accordance with subsection (A) above, the Employee may elect, in his absolute discretion, that the Company&#8217;s contributions be made to a pension fund (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Pension Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) for the benefit of the Employee. In such event, the Company shall pay, on a monthly basis, an amount equal to 14.83% of the Employee&#8217;s Base Salary (consisting of 6.5% for pension payments (or any other increased percentage as shall be updated from time to time by the Minister of Economy) and 8.33% for severance payments), and the Employee shall make contributions to such Pension Fund on a monthly basis in an amount equal to 6% (or any other increased percentage as shall be updated from time to time by the Minister of Economy) of the Employee&#8217;s Base Salary as a premium on the Pension Fund. Such amount to be contributed by the Employee shall be deducted by the Company from the Employee&#8217;s Base Salary and transferred to the Pension Fund.</font></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">C. The Employee agrees and acknowledges that payments by the Company under this Section 2 shall be in lieu of the Company&#8217;s statutory obligation to pay severance pay, in accordance with Section 14 of the Severance Pay Law, 5723-1963 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) and the approval of the Minister of Labor and Welfare, published on the Official Publications Gazette No. 4659, on June 30, 1998, as amended and published in the Official Publications Gazette No. 4803 on September 19, 1999, in the form translated and attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:107%">Appendix A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">and constituting an integral part hereof or any other updated approval, if and when issued.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:108pt"><font><br></font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Upon the termination of this Agreement for any reason whatsoever, the Company shall assign all rights in the Policy and&#47;or the Pension Fund, as the case may be, to the Employee, by directions in writing to the Insurance Company and&#47;or the custodian of the Pension Fund, as the case may be, and the issuance of the required Income Tax forms&#59; provided, however, that the following exceptions shall apply&#58; (i) in the event Employee&#8217;s right to severance pay has been deprived under a verdict according to Section 17 of the Law and to the extent so deprived, or (ii) in case Employee draws upon the Policy other than for an &#8220;Entitling Event&#8221; (&#8220;Eruah Mezake&#8221;) as defined in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">Appendix A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">), in such cases (i) and (ii) those portions of the Policy constituting the Company&#8217;s 8.33% contributions will be refunded to the Company.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.02pt;text-decoration:underline">Expense Reimbursement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Upon presentation of appropriate documentation, the Employee will be reimbursed in accordance with the Company&#8217;s expense reimbursement policy as in effect from time to time for all reasonable and necessary business expenses incurred in connection with the performance of the Employee&#8217;s duties and responsibilities hereunder.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.7pt;text-decoration:underline">Automobile Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. During the period from the Effective Date through December 31, 2025 only, the Company will provide the Employee on a monthly basis an amount in cash sufficient on an after-tax basis to cover car and car-related expenses of the Employee (other than parking fines and or other traffic violations) not to exceed $4,000 per month.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:6.03pt;text-decoration:underline">Military Reserve Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-23.76pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:107%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:18pt">Throughout any reserve service, in accordance with the provisions of applicable law, the Employee shall be entitled to full remuneration in respect of all payments and rights awarded by this Agreement.</font></div><div style="padding-left:72pt"><font><br></font></div><div style="padding-left:108pt;text-indent:-27.66pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">ii.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:18pt">The Employee is required at all times to provide the necessary documentation in connection therewith and for submission by the Company to the National Insurance Institution (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">NII</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) in order to claim such payments from the NII and the Company will have the right to claim such payments from the NII.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.02pt;text-decoration:underline">Equity Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. During the Term, the Employee shall be eligible to participate in the Parent&#8217;s 2024 Omnibus Incentive Plan and such other prior or future equity-based long-term incentive compensation plan, program or arrangement generally made available to similarly situated employees of the Company or the Parent, as the case may be, from time to time (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), as determined in the sole and absolute discretion of the board of directors of the Parent or a committee thereof. Notwithstanding the foregoing, Employee acknowledges that any awards granted under a Plan that are conditioned upon his continued employment under the terms of the Prior Agreement are forfeited.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9pt;text-decoration:underline">Term of Employment</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.7pt;text-decoration:underline">The Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Subject to early termination as set forth herein, the employment of the Employee shall be for and shall continue for a term of two years (the &#8220;Term&#8221;), </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">commencing on the Effective Date and ending on December 31, 2026 (the &#8220;End Date&#8221;). For purposes of this Agreement, &#8220;Good Reason&#8221; means termination by the Employee for any of the following reasons&#58; (i) the Company&#8217;s material failure to make any required payment to the Employee hereunder&#59; (ii) the substantial diminution of the Employee&#8217;s position, reporting relationship, duties or responsibilities through no fault of his own&#59; (iii) a reduction in the Employee&#8217;s Base Salary of more than ten percent (10%), unless such reduction is applied to all senior executives&#59; (iv) a requirement that the Employee move his principal business location that would increase his commute by more than thirty (30) miles from the location in effect of the Effective Date&#59; or (v) the Company&#8217;s willful breach of any of its material obligations under any written agreement with the Employee &#59; provided, however, the Employee shall not be permitted to resign for Good Reason unless (A) the Employee notifies the Company and Chief Executive Officer in writing of the occurrence of the alleged Good Reason condition within sixty (60) days of the Employee becoming aware of the occurrence of such condition&#59; (B) the Company shall have a period of not less than thirty (30) days following such notice (the &#8220;Cure Period&#8221;) to remedy the alleged condition, during which time the Employee cooperates in good faith with the Company&#8217;s efforts to remedy the condition&#59; (C) the alleged Good Reason condition is not remedied during the Cure Period&#59; and (D) the Employee terminates his employment within sixty (60) days after the end of the Cure Period. If the Company cures the alleged Good Reason condition during the Cure Period in the Employee&#8217;s reasonable good faith judgment, Good Reason shall be deemed not to have occurred.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.02pt;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Company may terminate the Employee&#8217;s employment under this Agreement at any time for Cause. For purposes of this Agreement, &#8220;Cause&#8221; shall mean a determination by the Board that any of the following have occurred&#58; (i) the Employee&#8217;s failure to follow the lawful and reasonable directives of the Company, the Chief Executive Officer or the Board&#59; (ii) the Employee&#8217;s material violation of any material Company policy, including any provision of a Code of Conduct or Code of Ethics adopted by the Company&#59; (iii) the Employee&#8217;s commission of any act of fraud, embezzlement, dishonesty or any other willful or gross misconduct that in the reasonable judgment of the Board has caused or is reasonably expected to result in material injury to the Company&#59; (iv) the Employee&#8217;s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom the Employee owes an obligation of nondisclosure as a result of the Employee&#8217;s relationship with the Company that in the reasonable judgment of the Board has caused or is reasonably expected to result in material injury to the Company&#59; (v) the Employee&#8217;s conviction of, or plea of guilty or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:107%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221; to, a felony or misdemeanor (other than a minor traffic offense)&#59; or (vi) the Employee&#8217;s material breach of any of his obligations under this Agreement or any written agreement between the Employee and the Company. Except for any such event or condition which, by its nature, cannot reasonably be expected to be cured, with respect to the events or conditions described in clauses (i), (ii) or (vi), the Employee shall have thirty (30) days after receipt of written notice from the Company specifying the events or conditions constituting Cause in reasonable detail within which to cure any events or conditions constituting Cause, provided that the Company serves notice of such events or conditions and intended termination within sixty (60) days of the occurrence thereof, and such Cause shall not exist unless either the Employee is not entitled to notice under this sentence, or, if the Employee is entitled to such notice, he fails to cure such acts constituting </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Cause within such thirty (30)-day cure period. Termination of the Employee&#8217;s employment shall not be deemed to be for Cause unless, prior to termination, the Company delivers to the Employee copies of resolutions duly adopted by the affirmative vote of not less than a majority of the Board (after reasonable written notice is provided to the Employee and he is given a reasonable opportunity, together with counsel, to be heard before the Board), finding that the Employee has engaged in the conduct described in any of (i)-(vi) above.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.7pt;text-decoration:underline">Termination Upon Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Company may terminate the Employee&#8217;s employment under this Agreement in the event of the Employee&#8217;s &#8220;Disability.&#8221; For purposes of this Agreement, &#8220;Disability&#8221; means that the Employee becomes ill or is injured so that he is unable to perform the duties required of him under this Agreement for a period of ninety (90) days. Upon such termination the Employee shall receive the Accrued Benefits.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.02pt;text-decoration:underline">Termination Other Than for Good Reason or for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Subject to the provisions of clauses (a) and (b) above, during the Term, upon sixty (60) days&#8217; prior written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Notice Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), the Company can terminate this Agreement other than for Cause and the Employee can terminate this Agreement other than for Good Reason. In the event the Employee delivers notice of his intention to terminate this Agreement other than for Good Reason, the Company may, in its sole discretion, (i) require the Employee to continue working during the Notice Period, in which case Employee will be entitled to his normal compensation under this Agreement during the Notice Period, (ii) relieve the Employee of some or all of his work responsibilities during the Notice Period or (iii) terminate the Employee&#8217;s employment immediately and provide the Employee with a payment in lieu of a Notice Period in the amount of the Employee's Base Salary through the expiration of the Notice Period. In no event shall the Company&#8217;s termination of the Employee&#8217;s employment following Employee&#8217;s delivery of written notice of his intention to resign constitute a termination of the Employee&#8217;s employment by the Company without Cause.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.8pt;text-decoration:underline">Transfer of Responsibilities&#59; Cooperation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Upon the expiration or termination of this Agreement, the Employee shall help assure the smooth transfer of responsibilities to his successor, by coordinating with his successor and helping familiarize him with the Company and the nature of the employment. In addition, upon the receipt of notice from the Company (including outside counsel), the Employee agrees that while employed by the Company and for a reasonable period thereafter, the Employee will respond and provide information with regard to matters in which the Employee has knowledge as a result of his employment with the Company, and will provide reasonable assistance to the Company and its representatives in defense of any claims that may be made against the Novocure Group, and will assist the Novocure Group in the prosecution of any claims that may be made by the Novocure Group, to the extent that such claims may relate to the period of the Employee&#8217;s employment with the Company (or any predecessor) and were within the Employee&#8217;s knowledge. The Employee agrees to promptly inform the Company if the Employee becomes aware of any lawsuits involving such claims that may be filed or threatened against the Company or another member of the Novocure Group. The Employee also agrees to promptly inform the Company (to the extent the Employee is legally permitted to do so) if the Employee is asked to assist in any investigation of the Company or another member of the Novocure Group (or its </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">actions), regardless of whether a lawsuit or other proceeding has then been filed against the Company or another member of the Novocure Group with respect to such investigation, and will not do so unless legally required.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:7.02pt;text-decoration:underline">Accrued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. Upon termination of the Employee&#8217;s employment for any reason, the Company will pay or provide the Employee&#58; (i) any unpaid Base Salary through the date of termination&#59; (ii) redemption of annual leave, if any&#59; (iii) reimbursement for any unreimbursed expenses incurred through the date of termination, in a lump sum in cash within thirty (30) days after the date of termination&#59; (iv) benefits in accordance with the terms of the applicable plans and programs of the Company&#59; (v) release of sums and payments in respect of the arrangements described in Section 2(d) in accordance with the terms thereof, within fifteen (15) days after the date of termination&#59; and (vi) redemption of recuperation pay (d&#8217;mey havra&#8217;ah), all in accordance with applicable law and the Company&#8217;s policies (items (i) through (vi) collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Accrued Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;).</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.02pt;text-decoration:underline">Certain Potential Additional Payments Upon Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.  </font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">In addition to the Accrued Benefits, upon a termination of the Employee&#8217;s employment within twelve (12) months following a Change in Control (as defined in the Plan), then the Company shall provide the Employee with the CIC Severance Adjustment if required to do so pursuant to this Section 3(g) and subject to the Employee&#8217;s timely execution of a waiver and release of claims in substantially the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:107%">Exhibit A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) within the time prescribed by the Company, the Company shall provide the Employee with the Severance Adjustment if required to do so pursuant to this Section 3(g). As soon as reasonably practicable following the date of the termination referenced above, the Company shall cause the Insurance Company, in the case of the Policy, and&#47;or the custodian of the Pension Fund, in the case of the Pension Fund, to determine the amount in the Policy and&#47;or the Pension Fund, as applicable, that is attributable to Company's contributions in respect of severance payments for the benefit of the Employee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Contributed Policy Value</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;). If the Employee is entitled to receive the CIC Severance Adjustment, the CIC Severance Adjustment will be paid to the Employee in a lump sum as soon as reasonably practicable following the determination of the Employee&#8217;s entitlement to the CIC Severance Adjustment. The determination of the Contributed Policy Value shall be final, binding and conclusive on the parties for the purpose of determining whether the Employee is entitled to the CIC Severance Adjustment. For purposes of this Section 3(g) only, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">CIC Severance Adjustment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221; shall be equal to the positive difference, if any, between (X) an aggregate amount equal to the product of (a) two hundred percent (200%) of Employee&#8217;s Base Salary that would have been payable through the End Date had Employee remained an Employee following the Change in Control through the End Date and (Y) the Contributed Policy Value. In addition, subject to the Employee&#8217;s execution and non-revocation of the Release, all stock options or other equity or equity-based awards held by the Employee that have not previously become vested and (if applicable) exercisable as of the date of the Qualifying Termination shall, upon such termination, become immediately and fully vested and exercisable, without regard to the terms of any applicable award agreement or plan document, and such awards shall otherwise continue to apply on the same terms.</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:11pt;font-weight:400;line-height:107%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:8.99pt;text-decoration:underline">Confidentiality and Proprietary Information</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.8pt">During the term of this Agreement and thereafter, the Employee shall preserve the confidentiality of all information relating to the business and activities of the Novocure Group, including all information relating to their technology, intellectual property, products, suppliers and clients, development and marketing plans, business strategy and business model, any other information of similar kind, and shall not reveal any such information to a third party of any kind, or use it in any way out of the Novocure Group, or transmit to third parties any information of a confidential nature that the Employee may have been given, without the consent of the Company. The foregoing shall not apply to information, which can be proven that is&#58; (i) generally available to the public, other than in violation of this Section 4(a)&#59; (ii) was already known to the Employee prior to the disclosure thereto by the Novocure Group&#59; (iii) was rightfully received by the Employee prior to the execution hereof from a third party without restriction on disclosure and without a breach of any confidentiality obligation running directly or indirectly to the Company or any member of the Novocure Group&#59; or (iv) was approved for release by a written authorization by the Company. Notwithstanding the foregoing or any other provision in this Agreement or otherwise, nothing herein shall prohibit the Employee from reporting possible violations of United States federal or state law or regulation to any governmental agency or entity or self-regulatory organization including but not limited to the Department of Justice, the Securities and Exchange Commission, Congress, and any agency Inspector General, or making other disclosures that are protected under the whistleblower provisions of United States federal or state law or regulation (it being understood that the Employee does not need the Company&#8217;s prior authorization to make any such reports or disclosures and the Employee is not required to notify the Company that he has made such reports or disclosures).</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.18pt">The Employee acknowledges and agrees that all trade secrets, works, concepts, drawings, materials, documentation, procedures, diagrams, specifications, models, processes, formulae, data, programs, knowhow, designs, techniques, ideas, methods, inventions, discoveries, improvements, work products or developments or other works of authorship (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Inventions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), whether patentable or unpatentable, (x) that relate to the Employee work with the Company or any other member of the Novocure Group, made, developed or conceived by him, solely or jointly with others or with the use of any of the Novocure Group&#8217;s equipment, supplies, facilities or trade secrets or (y) suggested by any work that the Employee performs in connection with the Novocure Group, either while performing his duties with the Novocure Group or on his own time, but only insofar as the Inventions are related to his work as an employee of the Novocure Group, will belong exclusively to the Company (or its designee and assigns), whether or not patent applications are filed thereon. The Employee will keep full and complete written records (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), in the manner prescribed by the Company, of all Inventions, and will promptly disclose all Inventions completely and in writing to the Company. The Records will be the sole and exclusive property of the Company (or its designee and assigns), and the Employee will surrender them upon the termination of his employment, or upon the Company&#8217;s request. The Employee hereby assigns to the Company (and its designees and assigns) the Inventions, including all rights in and to patents and other intellectual property rights that may issue thereon in any and all countries, whether during or subsequent to the term of this Agreement, together with the right to file, in his name or in the name of the Company (or its designee), applications for patents </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">and equivalent rights (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Applications</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;). The Employee will, at any time during and subsequent to the term of this Agreement, make such Applications, sign such papers, take all rightful oaths, and perform all acts as may be requested from time to time by the Company with respect to the Inventions and the underlying intellectual property. The Employee will also execute assignments to the Company (or its designee or assigns) of the Applications, and give the Company and its attorneys all reasonable assistance (including the giving of testimony) to obtain the Inventions and the underlying intellectual property for its benefit, all without additional compensation to the Employee from the Company, but entirely at the Company&#8217;s expense.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.8pt">In addition, the Inventions will be deemed &#8220;work made for hire,&#8221; as such term is defined under the copyright law of the United States, on behalf of the Novocure Group and the Employee agrees that the Novocure Group will be the sole owner of the Inventions, and all underlying rights therein, in all media now known or hereinafter devised, throughout the universe and in perpetuity without any further obligations or compensation to him. If the Inventions, or any portion thereof, are deemed not to be &#8220;work made for hire,&#8221; the Employee hereby irrevocably conveys, transfers, assigns and delivers to the Novocure Group, all rights, titles and interests in all media now known or hereinafter devised, throughout the universe and in perpetuity, in and to the Inventions and the underlying intellectual property, including without limitation, (A) all of his rights, titles and interests in the copyrights (and all renewals, revivals and extensions thereof) related to the Inventions and the underlying intellectual property&#59; (B) all rights of any kind or any nature now or hereafter recognized, including without limitation, the unrestricted right to make modifications, adaptations and revisions to the Inventions, to exploit and allow others to exploit the Inventions and the underlying intellectual property&#59; and (C) all rights to sue at law or in equity for any infringement, or other unauthorized use or conduct in derogation of the Inventions, known or unknown, prior to the date hereof, including without limitation the right to receive all proceeds and damages therefrom. In addition, the Employee hereby waives any so-called &#8220;moral rights&#8221; with respect to the Inventions. The Employee hereby waives any and all currently existing and future monetary rights in and to the Inventions and all patents and other intellectual property rights that may issue thereon, including, without limitation, any rights that would otherwise accrue to his benefit by virtue of the Employee being an employee of or other service provider to the Novocure Group. It is further agreed that the Employee&#8217;s Base Salary and any other benefits and&#47;or payments provided under this Agreement already include any consideration the Employee may be entitled to for Inventions developed or generated by him (or with Employee&#8217;s assistance or contribution, as provided above) in accordance with Section 134 of the Patents Law, 5727-1967), and the Employee shall not be entitled to receive any additional consideration in this respect whatsoever.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.18pt">To the extent that the Employee is unable to assign any of his right, title or interest in any Invention under applicable law, for any such Invention and the underlying intellectual property rights, the Employee hereby grants to the Novocure Group an exclusive, irrevocable, perpetual, transferable, worldwide, fully paid license to such Invention and the underlying intellectual property, with the right to sublicense, use, modify, create derivative works and otherwise fully exploit such Invention and the underlying intellectual property, to assign this license and to exercise all rights and incidents of ownership of the Invention.</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.8pt">To the extent that any of the Inventions are derived by, or require use by the Novocure Group of, any works, Inventions, or other intellectual property rights that the Employee owns, which are not assigned hereby, the Employee hereby grants to Novocure Group an irrevocable, perpetual, transferable, worldwide, non-exclusive, royalty free license, with the right to sublicense, use, modify and create derivative works using such works, Inventions or other intellectual property rights, but only to the extent necessary to permit the Novocure Group to fully realize their ownership rights in the Inventions.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Restrictive Covenants</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.8pt;text-decoration:underline">Non-Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. So long as the Employee is employed by the Company under this Agreement and for the twelve (12)-month period following the termination of the Employee&#8217;s employment with the Company for any reason (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Restricted Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), the Employee agrees that he will not, directly or indirectly, without the prior written consent of the Company, engage in Competition with the Novocure Group. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Competition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221; means participating, directly or indirectly, as an individual proprietor, partner, stockholder, officer, employee, director, joint venturer, investor, lender, consultant or in any other capacity whatsoever in any business or in the development of any business if (A) such business competes or would compete with the business of the Novocure Group (it being understood that the business of the Novocure Group is the development and commercialization of its proprietary tumor treating fields (TTF) therapy for the treatment of solid tumor cancers (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Business</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;)) and (B) the Employee&#8217;s activities related to such business would create the opportunity for the Employee to use confidential and proprietary information of the Novocure Group in connection with any other product being developed, manufactured, supplied or sold by any such business or business under development that competes with or upon introduction of a product would compete with the Business. For the avoidance of doubt and by way of example, the foregoing restrictions would not preclude the Employee from being employed by a pharmaceutical company during the Restricted Period to the extent that the Employee&#8217;s activities at such pharmaceutical company would not be directly related to the development, marketing or sale of products that are directly competitive with the Business. Notwithstanding the foregoing, nothing contained in this Section 5(a) shall prohibit the Employee from (i) investing, as a passive investor, in any publicly held company provided that the Employee&#8217;s beneficial ownership of any class of such publicly held company&#8217;s securities does not exceed one percent (1%) of the outstanding securities of such class, or (ii) with the consent of the Board, entering the employ of any academic institution or governmental or regulatory instrumentality of any country or any domestic or foreign state, county, city or political subdivision.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.18pt;text-decoration:underline">Non-Solicitation of Customers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Employee agrees that during the Restricted Period, he will not, directly or indirectly, solicit or influence, or attempt to solicit or influence, customers of the Novocure Group to purchase goods or services then sold by the Novocure Group from any other person or entity.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.8pt;text-decoration:underline">Non-Solicitation of Suppliers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Employee agrees that during the Restricted Period, he will not, directly or indirectly, solicit or influence, or attempt to solicit or influence, the Novocure Group&#8217;s suppliers to provide goods or services then </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">provided to the Novocure Group to any other person or entity in Competition with the Novocure Group.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.18pt;text-decoration:underline">Non-Solicitation of Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Employee recognizes that he will possess confidential information about other employees of the Novocure Group relating to their education, experience, skills, abilities, compensation and benefits, and inter-personal relationships with customers of the Novocure Group. The Employee recognizes that the information he possesses and will possess about these other employees is not generally known, is of substantial value to the Novocure Group in developing its business and in securing and retaining customers, and has been and will be acquired by the Employee because of his business position with the Novocure Group. The Employee agrees that, during the Restricted Period, he will not (x) directly or indirectly, individually or on behalf of any other person or entity solicit or recruit any employee of the Novocure Group to leave such employment for the purpose of being employed by, or rendering services to, the Employee or any person or entity unaffiliated with the Novocure Group, or (y) convey any such confidential information or trade secrets about other employees of the Novocure Group to any person or entity other than in the course of the Employee&#8217;s assigned duties hereunder and for the benefit of the Novocure Group or as otherwise required by law or judicial or administrative process.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.8pt;text-decoration:underline">Non-Disparagement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Employee and the Novocure Group agree that neither will, nor induce others to, Disparage the Novocure Group or any of its past or present officers, directors, employees or products, or the Employee. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Disparage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221; will mean making comments or statements to the press, the Novocure Group&#8217;s employees or any individual or entity with whom the Novocure Group has a business relationship, or any prospective new employer of the Employee, that would adversely affect in any manner&#58; (i) the conduct of the business of the Novocure Group (including, without limitation, any products or business plans or prospects)&#59; or (ii) the business reputation of the Novocure Group, or any of its products, or its past or present officers, directors, employees, stockholders and affiliates, or the Employee.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:7.02pt">The Employee acknowledges that the restrictions set under this Section 5 are fair and reasonable, and are essential for protection of the Novocure Group&#8217;s business, the Novocure Group&#8217;s proprietary rights and other legitimate interests of the Novocure Group, in view of the nature of the business in which the Novocure Group is engaged and its innovative course. The Employee further acknowledges that the above restrictions are customarily complied with by persons situated in a similar position, correspond with fair dealing requirements and are adequate in light of the Employee&#8217;s usage of Novocure Group resources during Employee&#8217;s employment hereunder. In addition, such restrictions are fully compensated for by the Base Salary and benefits provided hereunder, and are not likely to have a material adverse effect upon the Employee&#8217;s professional position and promotion opportunities during the Restricted Period.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.18pt;text-decoration:underline">No Disclosure to Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Employee represents and warrants that the Employee has not and will not disclose to the Company or any member of the Novocure Group any confidential information received by the Employee from any third party, and subject to restriction on disclosure, or through breach of confidentiality obligations, including without limitations any information received by </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">the Employee in connection with any prior employer-employee engagement by the Employee.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(h)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:5.18pt;text-decoration:underline">Injunctive Relief</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. It is further expressly agreed that the Novocure Group will or would suffer irreparable injury if the Employee were to violate the provisions of this Section 5, and that the Novocure Group would by reason of such violation be entitled to injunctive relief in a court of appropriate jurisdiction and the Employee further consents and stipulates to the entry of such injunctive relief in such court prohibiting him from violating the provisions of this Section 5.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:7.63pt">The obligations contained in this Section 5 will survive the termination of the Employee&#8217;s employment with the Company or any member of the Novocure Group and will be fully enforceable thereafter. If it is determined by a court of competent jurisdiction that any restriction in this Section 5 excessive in duration or scope or extends for too long a period of time or over too great a range of activities or in too broad a geographic area or is unreasonable or unenforceable under the laws of that state, it is the intention of the parties that such restriction may be modified or amended by the court to render it enforceable to the maximum extent permitted by applicable law.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">(j)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:7.63pt;text-decoration:underline">Return of Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. On the date of the termination of the Employee&#8217;s employment with the Company for any reason (or at any time prior thereto at the Company&#8217;s request), he will return all property belonging to the Novocure Group (including, but not limited to, any Novocure Group provided laptops, computers, cell phones, wireless electronic mail devices or other equipment, or documents and property belonging to the Novocure Group, but not his personal rolodex to the extent it contains only contact information).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Indemnification&#59; Directors and Officers Liability Insurance</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">In addition to any rights to indemnification to which the Employee may be entitled under the Company&#8217;s articles of association, the Company shall indemnify the Employee at all times during and after his employment terminates for any reason to the maximum extent permitted under applicable law, including its provisions regarding advancement of costs and attorneys&#8217; fees, in connection with any action, suit, investigation or proceeding based in whole or in part upon the Employee&#8217;s actions, inaction, or status as an employee, officer, or director of the Company, except to the extent it is finally determined by a court of competent jurisdiction that the Employee is either not entitled to indemnification hereunder or otherwise or that any such action or inaction by the Employee that gave rise to any such action, suit, investigation or proceeding arose out of his own gross negligence, willful misconduct or fraud. The Company shall maintain directors and officers liability insurance in commercially reasonable amounts (as reasonably determined by the Board), and the Employee shall be covered under such insurance to the same extent as any other senior executives of the Company, both during employment and thereafter while potential liability exists.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Assignment</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Notwithstanding anything else herein, this Agreement is personal to the Employee and neither the Agreement nor any rights hereunder may be assigned by the Employee. The Company may (subject to the written consent of the Employee if required by applicable </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Israeli law) assign the Agreement to another member of the Novocure Group or to any acquiror of all or substantially all of the assets of the Company or the Parent or otherwise to any person in connection with a Change in Control. This Agreement will inure to the benefit of and be binding upon the personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees, legatees and permitted assignees of the parties.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Counterparts</font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, and all of such counterparts shall constitute one and the same instrument, which may sufficiently be evidenced by any one counterpart.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Individual Agreement&#59; Entire Agreement</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">This Agreement is a special, individual agreement, contains the entire agreement of the parties with respect to the subject matters addressed herein, and as of the Effective Date, supersedes and replaces in its entirety the Prior Agreement. The collective agreements relating to the employees of the Novocure Group (if any) shall not apply to the Employee. Neither this Agreement nor any term of this Agreement may be amended, discharged or terminated orally, but only by a written instrument signed by the party to be bound thereby. No provision of this Agreement may be waived except in writing by the waiving party. No failure to exercise, delay in exercising, or single or partial exercise of any right, power or remedy by either party, and no course of dealing between the parties, shall constitute a waiver of, or shall preclude any other or further exercise of, any right, power or remedy. The provisions of this Agreement will be deemed severable and the invalidity of unenforceability of any provision will not affect the validity or enforceability of the other provisions hereof.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.25pt;text-decoration:underline">Compensation Recovery</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The payment of any payments that may be made to the Employee, whether under this Agreement or under the Prior Agreement, regardless of whether the amount of such payment is determined based on achievement of financial performance objectives, shall be subject to recoupment in accordance with any clawback policy that Parent and&#47;or the Company has adopted, adopts or is otherwise required by applicable law to adopt, whether pursuant to the listing standards of any national securities exchange or association on which the Parent&#8217;s securities are listed, the Dodd-Frank Wall Street Reform and Consumer Protection Act and&#47;or other applicable law. Any such recovered sum according to any clawback policy shall be deemed to be an agreed upon debt of the Employee to the Company and the Company shall be entitled to deduct any such recovered sum or any portion of it from any payment due to the Employee by the Company, all in accordance with applicable law.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.25pt;text-decoration:underline">Captions and Headings</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The captions and descriptive headings in this Agreement are inserted for convenience only and do not constitute a part of this Agreement.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.25pt;text-decoration:underline">Governing Law</font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">This Agreement will be governed by, and construed under and accordance with, the internal laws of the State of Israel, without reference to rules relating to conflicts of laws.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.25pt;text-decoration:underline">Taxes</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The Company may withhold from any and all amounts payable to the Employee such taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:4.25pt;text-decoration:underline">Notices</font></div><div><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Any notice required to be given pursuant to this Agreement shall be in writing and shall be deemed to have been sufficiently given if sent by registered mail, with all charges prepaid, addressed to the Company at its then principal executive offices (Attention&#58; General Counsel) or to the Employee at the last address in the Company&#8217;s records, or to either party at such other address as he or it may from time to time specify for such purpose in a notice similarly given.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">IN WITNESS WHEREOF, the parties have executed this Amended and Restated Agreement as of the Effective Date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">NovoCure (Israel) Ltd.                                                           Asaf Danziger</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">_____________________________                                      _________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Name&#58;  Title&#58; </font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Appendix A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Approval by Minister of Labor and Welfare</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">GENERAL APPROVAL REGARDING PAYMENTS BY EMPLOYERS TO A PENSION FUND AND INSURANCE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">FUND IN LIEU OF SEVERANCE PAY ACCORDING TO SEVERANCE PAY LAW, 5723-1963</font></div><div><font><br></font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">By virtue of my power under section 14 of the Severance Pay Law, 5723-1963 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), I certify that payments made by an employer commencing from the date of the publication of this approval publication for his employee to a comprehensive pension benefit fund that is not an insurance fund within the meaning thereof in the Income Tax Regulations (Rules for the Approval and Conduct of Benefit Funds), 5724-1964 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Pension Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;) or to managers insurance including the possibility of an insurance pension fund as aforesaid (hereinafter&#58; the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Insurance Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), including payments made by him by a combination of payments to a Pension Fund and an Insurance Fund (hereinafter&#58; the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Employer&#8217;s Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), shall be made in lieu of the severance pay due to the said employee in respect of the salary from which the said payments were made and for the period they were paid (hereinafter&#58; the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Exempt Salary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;), provided that all the following conditions are fulfilled&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(1)The Employer&#8217;s Payments &#8211;</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(a) To the Pension Fund are not less than 14-1&#47;3% of the Exempt Salary or 12% of the Exempt Salary if the employer pays for his employee in addition thereto also payments to supplement severance pay to a benefit fund for severance pay or to an Insurance Fund in the employee&#8217;s name in an amount of 2-1&#47;3% of the Exempt Salary. In the event the employer has not paid an addition to the said 12%, the employer&#8217;s payments shall be only in lieu of 72% of the employee&#8217;s severance pay&#59;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(b)To the Insurance Fund are not less than one of the following&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">13-1&#47;3% of the Exempt Salary, if the employer pays for his employee in addition thereto also payments to secure monthly income in the event of disability, in a plan approved by the Commissioner of the Capital Market, Insurance and Savings Department of the Ministry of Finance, in an amount required to secure at least 75% of the Exempt Salary or in an amount of 2-1&#47;2 % of the Exempt Salary, the lower of the two (hereinafter&#58; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Disability Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8221;)&#59;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">11% of the Exempt Salary, if the employer paid, in addition, a payment to the Disability Insurance, and in such case the Employer&#8217;s Payments shall only replace 72% of the Employee&#8217;s severance pay&#59; In the event the employer has paid in addition to the foregoing payments to supplement severance pay to a benefit fund for severance pay or to an Insurance Fund in the employee&#8217;s name in an amount of 2-1&#47;3 % of the Exempt Salary, the Employer&#8217;s Payments shall replace 100% of the employee&#8217;s severance pay.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">No later than three months from the commencement of the Employer&#8217;s Payments, a written agreement is executed between the employer and the employee in which &#8211;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The employee has agreed to the arrangement pursuant to this approval in a text specifying the Employer&#8217;s Payments, the Pension Fund and Insurance Fund, as the case may be&#59; the said agreement shall also include the text of this approval&#59;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The employer waives in advance any right, which it may have to a refund of monies from his payments, unless the employee&#8217;s right to severance pay has been revoked by a judgment by virtue of Section 16 and 17 of the Law, and to the extent so revoked and&#47;or the employee has withdrawn monies from the Pension Fund or Insurance Fund other than by reason of an entitling event&#59; in such regard &#8220;Entitling Event&#8221; means death, disability or retirement at after the age of 60.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">This approval is not such as to derogate from the employee&#8217;s right to severance pay pursuant to any law, collective agreement, extension order or employment agreement, in respect of salary over and above the Exempt Salary.</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">ACKNOWLEDGED AND AGREED&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">NovoCure (Israel) Ltd.                                                           Asaf Danziger</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">___________________________                                          _______________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Name&#58; Title&#58;</font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;text-indent:-49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">&#1488;&#1497;&#1513;&#1493;&#1512; &#1499;&#1500;&#1500;&#1497; &#1489;&#1491;&#1489;&#1512; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497; &#1502;&#1506;&#1489;&#1497;&#1491;&#1497;&#1501; &#1500;&#1511;&#1512;&#1503; &#1508;&#1504;&#1505;&#1497;&#1492; &#1493;&#1500;&#1511;&#1493;&#1508;&#1514; &#1489;&#1497;&#1496;&#1493;&#1495; &#1489;&#1502;&#1511;&#1493;&#1501; &#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501; &#1500;&#1508;&#1497; &#1495;&#1493;&#1511; &#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501;, &#1492;&#1514;&#1513;&#1499;&#34;&#1490; 1963-</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1489;&#1514;&#1493;&#1511;&#1507; &#1505;&#1502;&#1499;&#1493;&#1514;&#1497; &#1500;&#1508;&#1497; &#1505;&#1506;&#1497;&#1507; 14 &#1500;&#1495;&#1493;&#1511; &#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501;, &#1492;&#1514;&#1513;&#1499;&#34;&#1490; 1963- )&#1500;&#1492;&#1500;&#1503; -&#1492;&#1495;&#1493;&#1511;(, &#1488;&#1504;&#1497; &#1502;&#1488;&#1513;&#1512; &#1499;&#1497; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1501; &#1513;&#1513;&#1497;&#1500;&#1501; &#1502;&#1506;&#1489;&#1497;&#1491; &#1492;&#1495;&#1500; &#1489;&#1497;&#1493;&#1501; &#1508;&#1512;&#1505;&#1493;&#1502;&#1493; &#1513;&#1500;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1488;&#1497;&#1513;&#1493;&#1512; &#1494;&#1492;, &#1489;&#1506;&#1491; &#1506;&#1493;&#1489;&#1491;&#1493; &#1500;&#1508;&#1504;&#1505;&#1497;&#1492; &#1502;&#1511;&#1497;&#1508;&#1492; &#1489;&#1511;&#1493;&#1508;&#1514; &#1490;&#1502;&#1500; &#1500;&#1511;&#1510;&#1489;&#1492; &#1513;&#1488;&#1497;&#1504;&#1492; &#1511;&#1493;&#1508;&#1514; &#1489;&#1497;&#1496;&#1493;&#1495; &#1499;&#1502;&#1513;&#1502;&#1506;&#1493;&#1514;&#1492; &#1489;&#1514;&#1511;&#1504;&#1493;&#1514; &#1502;&#1505; &#1492;&#1499;&#1504;&#1505;&#1492; )&#1499;&#1500;&#1500;&#1497;&#1501; &#1500;&#1488;&#1497;&#1513;&#1493;&#1512; &#1493;&#1500;&#1504;&#1497;&#1492;&#1493;&#1500; &#1511;&#1493;&#1508;&#1493;&#1514; &#1490;&#1502;&#1500;(,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1492;&#1514;&#1513;&#1499;&#34;&#1491; 1964- )&#1500;&#1492;&#1500;&#1503; - &#1511;&#1512;&#1503; &#1508;&#1504;&#1505;&#1497;&#1492;(, &#1488;&#1493; &#1500;&#1489;&#1497;&#1496;&#1493;&#1495; &#1502;&#1504;&#1492;&#1500;&#1497;&#1501; &#1492;&#1499;&#1493;&#1500;&#1500; &#1488;&#1508;&#1513;&#1512;&#1493;&#1514; &#1500;&#1511;&#1510;&#1489;&#1492; &#1488;&#1493; &#1513;&#1497;&#1500;&#1493;&#1489; &#1513;&#1500; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1501; &#1500;&#1514;&#1499;&#1504;&#1497;&#1514; &#1511;&#1510;&#1489;&#1492; &#1493;&#1500;&#1514;&#1499;&#1504;&#1497;&#1514; &#1513;&#1488;&#1497;&#1504;&#1492; &#1500;&#1511;&#1510;&#1489;&#1492;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1489;&#1511;&#1493;&#1508;&#1514; &#1489;&#1497;&#1496;&#1493;&#1495; &#1499;&#1488;&#1502;&#1493;&#1512; )&#1500;&#1492;&#1500;&#1503; - &#1511;&#1493;&#1508;&#1514; &#1489;&#1497;&#1496;&#1493;&#1495;(, &#1500;&#1512;&#1489;&#1493;&#1514; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1501; &#1513;&#1513;&#1497;&#1500;&#1501; &#1514;&#1493;&#1498; &#1513;&#1497;&#1500;&#1493;&#1489; &#1513;&#1500; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1501; &#1500;&#1511;&#1512;&#1503; &#1508;&#1504;&#1505;&#1497;&#1492; &#1493;&#1500;&#1511;&#1493;&#1508;&#1514; &#1489;&#1497;&#1496;&#1493;&#1495; &#1489;&#1497;&#1503; &#1488;&#1501; &#1497;&#1513; &#1489;&#1511;&#1493;&#1508;&#1514;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1492;&#1489;&#1497;&#1496;&#1493;&#1495; &#1514;&#1499;&#1504;&#1497;&#1514; &#1500;&#1511;&#1510;&#1489;&#1492; &#1493;&#1489;&#1497;&#1503; &#1488;&#1501; &#1500;&#1488;&#1493; )&#1500;&#1492;&#1500;&#1503; - &#1514;&#1513;&#1500;&#1493;&#1502;&#1497; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491;(, &#1497;&#1489;&#1493;&#1488;&#1493; &#1489;&#1502;&#1511;&#1493;&#1501; &#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1492;&#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501; &#1492;&#1502;&#1490;&#1497;&#1506;&#1497;&#1501; &#1500;&#1506;&#1493;&#1489;&#1491; &#1492;&#1488;&#1502;&#1493;&#1512; &#1489;&#1490;&#1497;&#1503; &#1492;&#1513;&#1499;&#1512; &#1513;&#1502;&#1502;&#1504;&#1493; &#1513;&#1493;&#1500;&#1502;&#1493;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#58;&#1492;&#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1501; &#1492;&#1488;&#1502;&#1493;&#1512;&#1497;&#1501; &#1493;&#1500;&#1514;&#1511;&#1493;&#1508;&#1492; &#1513;&#1513;&#1493;&#1500;&#1502;&#1493; )&#1500;&#1492;&#1500;&#1503; - &#1492;&#1513;&#1499;&#1512; &#1492;&#1502;&#1493;&#1508;&#1496;&#1512;(, &#1493;&#1489;&#1500;&#1489;&#1491; &#1513;&#1504;&#1514;&#1511;&#1497;&#1497;&#1502;&#1493; &#1499;&#1500; &#1488;&#1500;&#1492;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">- &#1514;&#1513;&#1500;&#1493;&#1502;&#1497; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; . 1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1500;&#1511;&#1512;&#1503; &#1508;&#1504;&#1505;&#1497;&#1492; &#1488;&#1497;&#1504;&#1501; &#1508;&#1495;&#1493;&#1514;&#1497;&#1501; &#1502;&#8211; 14.33% &#1502;&#1503; &#1492;&#1513;&#1499;&#1512; &#1492;&#1502;&#1493;&#1508;&#1496;&#1512; &#1488;&#1493; 12% &#1502;&#1503; &#1492;&#1513;&#1499;&#1512; &#1492;&#1502;&#1493;&#1508;&#1496;&#1512; &#1488;&#1501; &#1502;&#1513;&#1500;&#1501; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1489;&#1506;&#1491; &#1506;&#1493;&#1489;&#1491;&#1493; &#1489;&#1504;&#1493;&#1505;&#1507; .&#1488;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1500;&#1499;&#1498; &#1490;&#1501; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1501; &#1500;&#1492;&#1513;&#1500;&#1502;&#1514; &#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501; &#1500;&#1511;&#1493;&#1508;&#1514; &#1490;&#1502;&#1500; &#1500;&#1508;&#1497;&#1510;&#1493;&#1497;&#1497;&#1501; &#1488;&#1493; &#1500;&#1511;&#1493;&#1508;&#1514; &#1489;&#1497;&#1496;&#1493;&#1495; &#1506;&#1500; &#1513;&#1501; &#1492;&#1506;&#1493;&#1489;&#1491; &#1489;&#1513;&#1497;&#1506;&#1493;&#1512; &#1513;&#1500; 2.33% &#1502;&#1503; &#1492;&#1513;&#1499;&#1512;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1492;&#1502;&#1493;&#1508;&#1496;&#1512;. &#1500;&#1488; &#1513;&#1497;&#1500;&#1501; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1489;&#1504;&#1493;&#1505;&#1507; &#1500;&#8211; 12% &#1490;&#1501; 2.33% &#1499;&#1488;&#1502;&#1493;&#1512;, &#1497;&#1489;&#1493;&#1488;&#1493; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1493; &#1489;&#1502;&#1511;&#1493;&#1501; 72% &#1502;&#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1492;&#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501; &#1513;&#1500; &#1492;&#1506;&#1493;&#1489;&#1491;,</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#59;&#1489;&#1500;&#1489;&#1491;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#58;&#1500;&#1511;&#1493;&#1508;&#1514; &#1489;&#1497;&#1496;&#1493;&#1495; &#1488;&#1497;&#1504;&#1501; &#1508;&#1495;&#1493;&#1514;&#1497;&#1501; &#1502;&#1488;&#1495;&#1491; &#1502;&#1488;&#1500;&#1492; .&#1489;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(1) &#1502;&#1503; &#1492;&#1513;&#1499;&#1512; &#1492;&#1502;&#1493;&#1508;&#1496;&#1512;, &#1488;&#1501; &#1502;&#1513;&#1500;&#1501; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1489;&#1506;&#1491; &#1506;&#1493;&#1489;&#1491;&#1493; &#1489;&#1504;&#1493;&#1505;&#1507; &#1500;&#1499;&#1498; &#1490;&#1501; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1501; &#1500;&#1492;&#1489;&#1496;&#1495;&#1514; &#1492;&#1499;&#1504;&#1505;&#1492; &#1495;&#1493;&#1491;&#1513;&#1497;&#1514; &#1489;&#1502;&#1511;&#1512;&#1492; &#1488;&#1493;&#1489;&#1491;&#1503; 13.33%</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1499;&#1493;&#1513;&#1512; &#1506;&#1489;&#1493;&#1491;&#1492;, &#1489;&#1514;&#1499;&#1504;&#1497;&#1514; &#1513;&#1488;&#1497;&#1513;&#1512; &#1492;&#1502;&#1502;&#1493;&#1504;&#1492; &#1506;&#1500; &#1513;&#1493;&#1511; &#1492;&#1492;&#1493;&#1503; &#1489;&#1497;&#1496;&#1493;&#1495; &#1493;&#1495;&#1505;&#1499;&#1493;&#1503; &#1489;&#1502;&#1513;&#1512;&#1491; &#1492;&#1488;&#1493;&#1510;&#1512;, &#1489;&#1513;&#1497;&#1506;&#1493;&#1512; &#1492;&#1491;&#1512;&#1493;&#1513; &#1500;&#1492;&#1489;&#1496;&#1495;&#1514; 75% &#1502;&#1503; &#1492;&#1513;&#1499;&#1512;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#59;(&#1492;&#1502;&#1493;&#1508;&#1496;&#1512; &#1500;&#1508;&#1495;&#1493;&#1514; &#1488;&#1493; &#1489;&#1513;&#1497;&#1506;&#1493;&#1512; &#1513;&#1500; 2.5% &#1502;&#1503; &#1492;&#1513;&#1499;&#1512; &#1492;&#1502;&#1493;&#1508;&#1496;&#1512;, &#1500;&#1508;&#1497; &#1492;&#1504;&#1502;&#1493;&#1498; &#1502;&#1489;&#1497;&#1504;&#1497;&#1492;&#1501; )&#1500;&#1492;&#1500;&#1503; - &#1514;&#1513;&#1500;&#1493;&#1501; &#1500;&#1489;&#1497;&#1496;&#1493;&#1495; &#1488;&#1493;&#1489;&#1491;&#1503; &#1499;&#1493;&#1513;&#1512; &#1506;&#1489;&#1493;&#1491;&#1492;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(2) &#1502;&#1503; &#1492;&#1513;&#1499;&#1512; &#1492;&#1502;&#1493;&#1508;&#1496;&#1512;, &#1488;&#1501; &#1513;&#1497;&#1500;&#1501; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1489;&#1504;&#1493;&#1505;&#1507; &#1490;&#1501; &#1514;&#1513;&#1500;&#1493;&#1501; &#1500;&#1489;&#1497;&#1496;&#1493;&#1495; &#1488;&#1493;&#1489;&#1491;&#1503; &#1499;&#1493;&#1513;&#1512; &#1506;&#1489;&#1493;&#1491;&#1492;, &#1493;&#1489;&#1502;&#1511;&#1512;&#1492; &#1494;&#1492; &#1497;&#1489;&#1493;&#1488;&#1493; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; 11%</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1489;&#1502;&#1511;&#1493;&#1501; 72% &#1502;&#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1492;&#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501; &#1513;&#1500; &#1492;&#1506;&#1493;&#1489;&#1491;, &#1489;&#1500;&#1489;&#1491;&#59; &#1513;&#1497;&#1500;&#1501; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1504;&#1493;&#1505;&#1507; &#1506;&#1500; &#1488;&#1500;&#1492; &#1490;&#1501; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1501; &#1500;&#1492;&#1513;&#1500;&#1502;&#1514; &#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501; &#1500;&#1511;&#1493;&#1508;&#1514;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1490;&#1502;&#1500; &#1500;&#1508;&#1497;&#1510;&#1493;&#1497;&#1497;&#1501; &#1488;&#1493; &#1500;&#1511;&#1493;&#1508;&#1514; &#1489;&#1497;&#1496;&#1493;&#1495; &#1506;&#1500; &#1513;&#1501; &#1492;&#1506;&#1493;&#1489;&#1491; &#1489;&#1513;&#1497;&#1506;&#1493;&#1512; &#1513;&#1500; 2.33% &#1502;&#1503; &#1492;&#1513;&#1499;&#1512; &#1492;&#1502;&#1493;&#1508;&#1496;&#1512;, &#1497;&#1489;&#1493;&#1488;&#1493; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1489;&#1502;&#1511;&#1493;&#1501; 100%</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.&#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1492;&#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501; &#1513;&#1500; &#1492;&#1506;&#1493;&#1489;&#1491;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">- &#1500;&#1488; &#1497;&#1488;&#1493;&#1495;&#1512; &#1502;&#1513;&#1500;&#1493;&#1513;&#1492; &#1495;&#1493;&#1491;&#1513;&#1497;&#1501; &#1502;&#1514;&#1495;&#1497;&#1500;&#1514; &#1489;&#1497;&#1510;&#1493;&#1506; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1504;&#1506;&#1512;&#1498; &#1492;&#1505;&#1499;&#1501; &#1489;&#1499;&#1514;&#1489; &#1489;&#1497;&#1503; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1500;&#1489;&#1497;&#1503; &#1492;&#1506;&#1493;&#1489;&#1491; &#1493;&#1489;&#1493; . 2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1492;&#1505;&#1499;&#1502;&#1514; &#1492;&#1506;&#1493;&#1489;&#1491; &#1500;&#1492;&#1505;&#1491;&#1512; &#1500;&#1508;&#1497; &#1488;&#1497;&#1513;&#1493;&#1512; &#1494;&#1492; &#1489;&#1504;&#1493;&#1505;&#1495; &#1492;&#1502;&#1508;&#1512;&#1496; &#1488;&#1514; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1493;&#1488;&#1514; &#1511;&#1512;&#1503; &#1492;&#1508;&#1504;&#1505;&#1497;&#1492; &#1493;&#1511;&#1493;&#1508;&#1514; &#1492;&#1489;&#1497;&#1496;&#1493;&#1495;, &#1500;&#1508;&#1497; &#1492;&#1506;&#1504;&#1497;&#1503;&#59; &#1489;&#1492;&#1505;&#1499;&#1501; .&#1488;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#59;&#1492;&#1488;&#1502;&#1493;&#1512; &#1497;&#1497;&#1499;&#1500;&#1500; &#1490;&#1501; &#1504;&#1493;&#1505;&#1495;&#1493; &#1513;&#1500; &#1488;&#1497;&#1513;&#1493;&#1512; &#1494;&#1492;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1493;&#1497;&#1514;&#1493;&#1512; &#1492;&#1502;&#1506;&#1489;&#1497;&#1491; &#1502;&#1512;&#1488;&#1513; &#1506;&#1500; &#1499;&#1500; &#1494;&#1499;&#1493;&#1514; &#1513;&#1497;&#1499;&#1493;&#1500;&#1492; &#1500;&#1492;&#1497;&#1493;&#1514; &#1500;&#1493; &#1500;&#1492;&#1495;&#1494;&#1512; &#1499;&#1505;&#1508;&#1497;&#1501; &#1502;&#1514;&#1493;&#1498; &#1514;&#1513;&#1500;&#1493;&#1502;&#1497;&#1493;, &#1488;&#1500;&#1488; &#1488;&#1501; &#1499;&#1503; &#1504;&#1513;&#1500;&#1500;&#1492; &#1494;&#1499;&#1493;&#1514; &#1492;&#1506;&#1493;&#1489;&#1491; &#1500;&#1508;&#1497;&#1510;&#1493;&#1497;&#1497; .&#1489;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501; &#1489;&#1508;&#1505;&#1511; &#1491;&#1497;&#1503; &#1502;&#1499;&#1493;&#1495; &#1505;&#1506;&#1497;&#1508;&#1497;&#1501; 16 &#1488;&#1493; 17 &#1500;&#1495;&#1493;&#1511; &#1493;&#1489;&#1502;&#1497;&#1491;&#1492; &#1513;&#1504;&#1513;&#1500;&#1500;&#1492; &#1488;&#1493; &#1513;&#1492;&#1506;&#1493;&#1489;&#1491; &#1502;&#1513;&#1498; &#1499;&#1505;&#1508;&#1497;&#1501; &#1502;&#1511;&#1512;&#1503; &#1492;&#1508;&#1504;&#1505;&#1497;&#1492; &#1488;&#1493; &#1502;&#1511;&#1493;&#1508;&#1514; &#1492;&#1489;&#1497;&#1496;&#1493;&#1495;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.&#1513;&#1500;&#1488; &#1489;&#1513;&#1500; &#1488;&#1497;&#1512;&#1493;&#1506; &#1502;&#1494;&#1499;&#1492;&#59; &#1500;&#1506;&#1504;&#1497;&#1503; &#1494;&#1492;, &#34;&#1488;&#1497;&#1512;&#1493;&#1506; &#1502;&#1494;&#1499;&#1492;&#34; - &#1502;&#1493;&#1493;&#1514;, &#1504;&#1499;&#1493;&#1514; &#1488;&#1493; &#1508;&#1512;&#1497;&#1513;&#1492; &#1489;&#1490;&#1497;&#1500; &#1513;&#1497;&#1513;&#1497;&#1501; &#1488;&#1493; &#1497;&#1493;&#1514;&#1512;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1488;&#1497;&#1503; &#1489;&#1488;&#1497;&#1513;&#1493;&#1512; &#1494;&#1492; &#1499;&#1491;&#1497; &#1500;&#1490;&#1512;&#1493;&#1506; &#1502;&#1494;&#1499;&#1493;&#1514;&#1493; &#1513;&#1500; &#1506;&#1493;&#1489;&#1491; &#1500;&#1508;&#1497;&#1510;&#1493;&#1497;&#1497; &#1508;&#1497;&#1496;&#1493;&#1512;&#1497;&#1501; &#1500;&#1508;&#1497; &#1492;&#1495;&#1493;&#1511;, &#1492;&#1505;&#1499;&#1501; &#1511;&#1497;&#1489;&#1493;&#1510;&#1497;, &#1510;&#1493; &#1492;&#1512;&#1495;&#1489;&#1492; &#1488;&#1493; &#1495;&#1493;&#1494;&#1492; &#1506;&#1489;&#1493;&#1491;&#1492;, &#1489;&#1490;&#1497;&#1503; &#1513;&#1499;&#1512; &#1513;&#1502;&#1506;&#1489;&#1512; &#1500;&#1513;&#1499;&#1512; . 3</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.&#1492;&#1502;&#1493;&#1508;&#1496;&#1512;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(&#1496;&#34;&#1493; &#1489;&#1505;&#1497;&#1493;&#1503; &#1492;&#1514;&#1513;&#1504;&#34;&#1495; ) 9 &#1489;&#1497;&#1493;&#1504;&#1497; 1998</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#1488;&#1500;&#1497;&#1492;&#1493; &#1497;&#1513;&#1497;, &#1513;&#1512; &#1492;&#1506;&#1489;&#1493;&#1491;&#1492; &#1493;&#1492;&#1512;&#1493;&#1493;&#1495;&#1492;</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Exhibit A</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Form of Release Agreement</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">This </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">RELEASE AGREEMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">(&#8220;Agreement&#8221;) made this &#91; &#93;, &#91; &#93; (the &#8220;Effective Date&#8221;), between NovoCure (Israel) Ltd. (including its successors and assigns, the &#8220;Company&#8221;), and Asaf Danziger (the &#8220;Employee&#8221;).</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:10.37pt">In consideration of the amounts to be paid by the Company pursuant to Section 3(g) of the employment agreement, dated as of January 1, 2025 (the &#8220;Employment Agreement&#8221;), the Employee, on behalf of himself and his heirs, executors, devisees, successors and assigns, knowingly and voluntarily releases, remises, and forever discharges the Company and its parent company, subsidiaries and affiliates, together with each of their current and former principals, officers, directors, shareholders, agents, representatives and employees, and each of their heirs, executors, successors and assigns (collectively, the &#8220;Releasees&#8221;), from any and all debts, demands, actions, causes of action, accounts, covenants, contracts, agreements, claims, damages, omissions, promises, and any and all claims and liabilities whatsoever, of every name and nature, known or unknown, suspected or unsuspected, both in law and equity (&#8220;Claims&#8221;), which the Employee ever had, now has, or may hereafter claim to have against the Releasees by reason of any matter or cause whatsoever arising from the beginning of time to the time he signs this Agreement arising out of his employment by, or termination from employment by, the Company or the Novocure Group (the &#8220;General Release&#8221;). References herein to the &#8220;Novocure Group&#8221; shall mean and refer to, collectively, the Company, Novocure Limited, a Jersey (Channel Islands) corporation, and their respective direct and indirect subsidiaries and affiliates. This General Release of Claims shall apply to any Claim of any type, including, without limitation, any and all Claims of any type that the Employee may have arising under any applicable law and&#47;or under any policy, agreement, contract, understanding or promise, written or oral, formal or informal, between any of the Releasees and the Employee and shall further apply, without limitation, to any and all Claims in connection with, related to or arising out of the Employee&#8217;s employment relationship, or the termination of his employment, with the Company.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt">For the purpose of implementing a full and complete release, the Employee understands and agrees that this Agreement is intended to include all claims, if any, which the Employee or his heirs, executors, devisees, successors and assigns may have and which the Employee does not now know or suspect to exist in his favor against the Releasees, from the beginning of time until the time he signs this Agreement, and this Agreement extinguishes those claims.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:10.37pt">The Employee acknowledges and agrees that the Company has fully satisfied any and all obligations owed to him arising out of his employment with or termination from the Company, and no further sums or benefits are owed to him by the Company or by any of the other Releasees at any time.</font></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt">Excluded from this General Release are any claims which cannot be waived by law in a private agreement between employer and employee. Additionally, this General Release does not waive any right the Employee may have (i) to accrued and vested benefits or benefits otherwise due under any applicable law (such as salary, severance pay, redemption of annual leave and recuperation pay, advance notice </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div style="margin-top:6pt;padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">according to the applicable law, etc.) or (ii) to coverage and&#47;or indemnification by the Company pursuant to any directors&#8217; and officers&#8217; liability insurance coverage of the Company or pursuant to the organizational or governance documents of the Company.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Consultation with Attorney&#59; Voluntary Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Company advises the Employee to consult with an attorney of his choosing prior to signing this Agreement. The Employee understands and agrees that he has the right and has been given the opportunity to review this Agreement and, specifically, the General Release in Section 1 above, with an attorney. The Employee also understands and agrees that he is under no obligation to consent to the General Release set forth in Section 1 above. Employee acknowledges and agrees that the payments to be made to the Employee pursuant to Section 3(g) of the Employment Agreement are sufficient consideration to require him to abide with his obligations under this Agreement, including but not limited to the General Release set forth in Section 1. The Employee represents that he has read this Agreement, including the General Release set forth in Section 1, and understands its terms and that he enters into this Agreement freely, voluntarily, and without coercion.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Effective Date&#59; Revocation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. The Employee acknowledges and represents that he has been given forty-five (45) days during which to review and consider the provisions of this Agreement and, specifically, the General Release set forth in Section 1 above. The Employee further acknowledges and represents that he has been advised by the Company that he has the right to revoke this Agreement for a period of seven (7) days after signing it. The Employee acknowledges and agrees that, if he wishes to revoke this Agreement, he must do so in a writing, signed by him and received by the Company no later than 5&#58;00 p.m. Eastern Time on the seventh (7th) day of the revocation period. If no such revocation occurs, the General Release and this Agreement shall become effective on the eighth (8th) day following his execution of this Agreement.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. In the event that any one or more of the provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remainder of the Agreement shall not in any way be affected or impaired thereby.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. This Agreement and any other document or instrument delivered pursuant hereto, and all claims or causes of action that may be based upon, arise out of or relate to this Agreement will be governed by, and construed under and in accordance with, the internal laws of the State of Israel, without reference to rules relating to conflicts of laws.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. This Agreement, the Employment Agreement and the other agreements referred to in the Employment Agreement constitute the entire agreement and understanding of the parties with respect to the subject matter herein and supersedes all prior agreements, arrangements and understandings, written or oral, between the parties. The Consideration period to be determined at time of termination. The Employee acknowledges and agrees that he is not relying on any representations or promises by any representative of the Company concerning the meaning of any aspect of this Agreement.</font></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:9.75pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the dates set forth below.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">NOVOCURE (ISRAEL) LTD.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">__________________________________ </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">By&#58; </font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:64.8pt;width:100%"><div style="margin-bottom:0.1pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:133%">Exhibit 10.2</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Name&#58; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Title&#58;</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Asaf Danziger</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">_______________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Dated&#58;__</font></div><div style="height:64.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.1pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nvcr-20240830.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8a1f6b7d-0ca3-4369-ad4c-e8a2ec75a71f,g:41cf253c-f72f-4fea-b849-5125654aacb5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nvcr="http://www.novocure.com/20240830" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.novocure.com/20240830">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvcr-20240830_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nvcr-20240830_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformationDocument" roleURI="http://www.novocure.com/role/DocumentandEntityInformationDocument">
        <link:definition>0000001 - Document - Document and Entity Information Document</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>nvcr-20240830_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8a1f6b7d-0ca3-4369-ad4c-e8a2ec75a71f,g:41cf253c-f72f-4fea-b849-5125654aacb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4f9d6544-8bcd-485c-b325-d89f16c013cb_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_518d023e-4521-4d15-b50d-69b613502bfb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_accb2711-7769-4bfa-92ee-922162581e98_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_f7f9a259-17f8-495a-8fca-dd15dc861507_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_4416d901-c19b-4243-82c4-43e073b00a9d_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_9ff16308-a01f-4f6a-8d48-254e81a116f5_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_b0b7932f-221e-495b-8a15-ee2d50629416_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_966db90c-0248-4992-a83b-6f3dd4856e93_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_dc920f76-2dd1-4f3a-a1e0-19af4ce7c2b5_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_42d97ae9-6dfe-4766-82d1-35d3c76463af_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_cd455138-de78-4d47-aada-5cf490316d7e_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_cc62937d-a770-42b9-93b9-d8d6b0469f76_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_937ca2de-cb68-4ec3-965b-5a03526409b2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_71d15d9a-18b2-4187-b509-aacdb2cae6a2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_12b09fd6-6278-46f6-9d5a-beb4acb2a605_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_92214b17-0d2e-408c-8575-bd70b7f9664d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8cdb23f9-feb4-4b0e-80f7-0894151c7dc8_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_11566fca-b458-4d3d-9749-96a2b1f01acd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_61d78f70-00a2-4637-9b27-cf6bc060cf68_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_99fcbbfd-2aef-4de6-adc1-c27d01ed93c1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_ecaa54a9-cf01-43ed-959c-503a56259941_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_b2a92ae4-e211-4ba9-8fd6-adcb12a8bc1b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_520874c1-fc94-4d8d-beea-d185abb4c4ab_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>nvcr-20240830_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:8a1f6b7d-0ca3-4369-ad4c-e8a2ec75a71f,g:41cf253c-f72f-4fea-b849-5125654aacb5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.novocure.com/role/DocumentandEntityInformationDocument" xlink:type="simple" xlink:href="nvcr-20240830.xsd#DocumentandEntityInformationDocument"/>
  <link:presentationLink xlink:role="http://www.novocure.com/role/DocumentandEntityInformationDocument" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6e3f302e-50db-427f-afdc-71396587dbde" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_DocumentType_6e3f302e-50db-427f-afdc-71396587dbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8bcc6399-1f8e-4678-959b-dbf6d797ea0e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_DocumentPeriodEndDate_8bcc6399-1f8e-4678-959b-dbf6d797ea0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e7c30dee-6f5e-483c-929d-f7bf209d3bdf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityRegistrantName_e7c30dee-6f5e-483c-929d-f7bf209d3bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0e2c8c53-b3ae-4933-93b7-4cc8557feaef" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityCentralIndexKey_0e2c8c53-b3ae-4933-93b7-4cc8557feaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_61f46b3f-6d46-48f3-993b-0c8f8223c974" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_AmendmentFlag_61f46b3f-6d46-48f3-993b-0c8f8223c974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_246bf51c-140c-48dd-931e-b2ab14af0d5c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_246bf51c-140c-48dd-931e-b2ab14af0d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_2c62e442-18af-47eb-90d8-c753cd08f2d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityFileNumber_2c62e442-18af-47eb-90d8-c753cd08f2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_58f42737-e256-4ed5-86de-5f732784c9a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityTaxIdentificationNumber_58f42737-e256-4ed5-86de-5f732784c9a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8dc2ddd4-023c-46b0-acc2-164c69394663" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityAddressAddressLine1_8dc2ddd4-023c-46b0-acc2-164c69394663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c6f8a3c5-4364-4c75-b139-93c1286eca94" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityAddressCityOrTown_c6f8a3c5-4364-4c75-b139-93c1286eca94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_afb5be0d-390e-44af-ae99-628e1f792d5b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityAddressCountry_afb5be0d-390e-44af-ae99-628e1f792d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0e413024-e1a7-45e3-9251-64c3f328ea8e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityAddressPostalZipCode_0e413024-e1a7-45e3-9251-64c3f328ea8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_94bbac1f-0b22-4203-8ba9-1803091f22b4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_CityAreaCode_94bbac1f-0b22-4203-8ba9-1803091f22b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_061ea545-5a38-44b0-b080-ec84218aba7b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_LocalPhoneNumber_061ea545-5a38-44b0-b080-ec84218aba7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_838bc414-e4fc-49e3-ab36-61001986c3d3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_WrittenCommunications_838bc414-e4fc-49e3-ab36-61001986c3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_044617aa-9efc-4bb4-b665-d83c619b9381" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_SolicitingMaterial_044617aa-9efc-4bb4-b665-d83c619b9381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_7d5bd2c5-e17e-4bcf-b28c-da6b571d0ac9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_PreCommencementTenderOffer_7d5bd2c5-e17e-4bcf-b28c-da6b571d0ac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_a259823f-5d08-41c9-86d8-c92ceba84150" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_a259823f-5d08-41c9-86d8-c92ceba84150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_302f97b8-6475-4792-bc66-46bda8e7d22c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_Security12bTitle_302f97b8-6475-4792-bc66-46bda8e7d22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ac46108c-8f40-435f-bc6d-7c17994beb0c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_TradingSymbol_ac46108c-8f40-435f-bc6d-7c17994beb0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d37e2c70-6acd-48ea-b56e-7f95fd357964" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_SecurityExchangeName_d37e2c70-6acd-48ea-b56e-7f95fd357964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_7ee80a38-163b-4875-ac63-6ab55bc36a9e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_a0e1a51a-75d8-4195-8169-1c54698a81a5" xlink:to="loc_dei_EntityEmergingGrowthCompany_7ee80a38-163b-4875-ac63-6ab55bc36a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm45475934588496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information Document<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th"><div>Oct. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NovoCure Limited<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001645113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Y9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1057807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">No. 4 The Forum, Grenville Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">St. Helier<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">JE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">JE2 4UF<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">44 (0) 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">3475 6700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, no par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NVCR<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M=>Y!L/?P&HT=S8\?M_P!4$L#!!0    ( -.>D%DD'INBK0   /@!   :
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=
M6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\
MI%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X
M\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P6B#BR2!M:59]L$].
MM.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " #3GI!999!YDAD!  #/ P
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M<' N>&UL4$L! A0#%     @ TYZ060H"6V?O    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ TYZ069E<G",0
M!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #3GI!96_4 T(@$   P$0  &               @($."
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ TYZ069^@&_"Q
M @  X@P   T              ( !S P  'AL+W-T>6QE<RYX;6Q02P$"% ,4
M    " #3GI!9EXJ[',     3 @  "P              @ &H#P  7W)E;',O
M+G)E;'-02P$"% ,4    " #3GI!9'#AEZC\!   \ @  #P
M@ &1$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ TYZ0620>FZ*M
M^ $  !H              ( !_1$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ TYZ06660>9(9 0  SP,  !,              ( !
MXA(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  +!0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="nvcr-20240830.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information Document</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.novocure.com/role/DocumentandEntityInformationDocument</Role>
      <ShortName>Document and Entity Information Document</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K/A" isOnlyDei="true" original="nvcr-20240830.htm">nvcr-20240830.htm</File>
    <File>nvcr-20240830.xsd</File>
    <File>nvcr-20240830_lab.xml</File>
    <File>nvcr-20240830_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "nvcr-20240830.htm": {
   "nsprefix": "nvcr",
   "nsuri": "http://www.novocure.com/20240830",
   "dts": {
    "inline": {
     "local": [
      "nvcr-20240830.htm"
     ]
    },
    "schema": {
     "local": [
      "nvcr-20240830.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "nvcr-20240830_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nvcr-20240830_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.novocure.com/role/DocumentandEntityInformationDocument",
     "longName": "0000001 - Document - Document and Entity Information Document",
     "shortName": "Document and Entity Information Document",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvcr-20240830.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "nvcr-20240830.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.novocure.com/role/DocumentandEntityInformationDocument"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001645113-24-000036-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001645113-24-000036-xbrl.zip
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MH 1)0?KI>L;FC;W +T@@',PG2H24[)*Q'W>%9O;>W%^_?OCT&Q8U.28P2+R
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M;1+54Z&'E#7.G4),)M4CN_4SY:]MO79F1>]]+^5UVS+RAO#FPU,0-514%@^
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M_;C<ZD/7@JX@ 1PX.YS2A)P,=^TW7/S3]Q.M0B5,1[VAG8A3J$DY-8/R6?J
M?LH T_W3>X\>[## -+8(4]0Y)1VRTX5'4.0J6>E4C(*'80Z;E[IDE[*!%1[#
M[ZXG2BC=R:KEFA4$H03X)OR[I JDMXVD,V+X2/\Z]-B=KKITMG/KC!TV9ZCF
MW3VI;VCAZ8[NA%?#5.W%V0E*[^5&@3NPDG) 7!;Z!--%YF!T6\PZ2)6?XYEJ
M2VHQKIU9!C=LJ9O6)>3H1B$O6%NSQQ&Q[U(X9..&!?;)^#U<B@X+T-@& J-A
MFL8[*PR1$WV#/78DTB!L _?\6C O*49'2CNEXE0VH*(>B]=)R<Z&I9'%!,.:
MIM .3@6+"C+-_F'+GT86V@<*RJM-W)0(G:@O@2OIO.8].W?'"M,_Z8)2KRB<
MBZX=&$-B&6$BSHI[2/M]V.?!^("7DDK8[P]C8U;":A>FS-U1 TN\I5S2RNV%
MZVPO*+[\NN6Y0\??1=$^LUK&YN,> NE]&#)H%U4>YT!4KI:-"E<';Y[<M?[5
MHLPX6#!%91JG4/!6..R._]M'W4AB67K>N95$K$3-JP2-APSQW%K&\4R:<HH6
MOO8N,CN@;>EJ6U%Q,YV"PV 0T+6N9AWD0_RV7@"WI2!I?6T]?I2ZBSC]<VT,
MP&^";XY9%"[CSTN4JP7<+I%Q:%ZB!HR-F4A9K10-@9C,ZBA3! H0;;>HL&*8
M5R[@=JYR'L0GV!C:N^ 4J&BH09LANA[IA$."$8QQYEO8B <,' -ZZ4\1)HA6
M?#LV)AZ!P3H!(:&HFYZ/UCJ *"S I:F;U@%,!73;"^+Z\R606U=+TC<*/JF=
M__#>T\>[M//'9NB_&Z38(DNP98>2^E:+W;;N6B=BG+ P8=/$19[\D75M(7H4
M$T[DD',0/GQCK]-91]%UGM517/MF'@">2!>W3./&2:FS_9"5P!FPTIW*\;FF
MTL:*>B/!RZ%/ZNGK;O]*Z4"\S!)]" [L>&Y0[R"%%-/A(6;]DG%/G-WVXH"N
M)\_/*90/GE<X 13<<:\J DI:=^E8U["QFA'"G>S!#HU81Z1]XMN]4YC(Y?@O
M=Y3OWG#I:TFEIPX:9VK.D_>B:.0J2H81KF#/L[RI-B*X(=H#W#7"0<U\*0+?
MZNMO.!8UW/;B8E?4Z.+7U5H5: =A$,%?N!M?1TZ$;;F1B ^5_B,;ZW6SY8J2
MIUU09:D1<$/\N16^]L+<)OJ!X7B2#S#Q@NNH$ P>;FHP17J6SI<"ZIOO$ZCO
MN7 CW34,V-6K_]OE"\GY6#;2@ @MUWX<.PZ](Z,E%E!C#L[J8I..GD$6VUC?
MQ$ZZ"AOEB[14G B0#@1-1 [GLZ;<CRUW%+E4X!U7H8FKX]IO+I"[H"91P,(Z
M0 ,"?,'2XVW<S.V*E&(W:TT3&$YB#-=7NC1('ZQ.[NB4S)/ 5VH6D0,T$=HD
M-5-(Z#F('?%3XWD,34"D(I8&N';;USQPD*IE$"?OF$YQ&!PA(.GHD;[[U;7]
M(PY\+8;.25=4-1,PK^!,N(9&-(K?QVY):!4@!7P\.L.;J,>7#AV^")VO5K8U
MI#TNJ^+2J\"!Q6%<#*%X2(6B[M^^.6Y^F'6[T20/N@OLG!L"\Q=K49L2!,V1
MFN/0O1?!'>R%- 7DDR#>C5#N=J,>_;H3!B89IBNN*'[-5ZJ08A67BE=NN8(]
M$%4QS)50+5 =,*_6]O79B%(([UTTW^A\$[8?7]HU1G3+XHHW8;G?AC;SW+T*
MX?^NK?%=1/9/%Y'=(5])I"%"E"J& EA--=_-O-MX8[,?Y40W*[Q.:ZFXO$[%
MICT8 >E0LYA0%35ELKERZX@(*-&- K5_5$V/EE5VH1N7LD9YR-W6AH"84AGN
M[;POQM#^7$&O&Q5#/[[:SGX#OF--,OVUN&%WYO9.7OWG,B0(Y$Y^;/^LJLN;
M+(D(-)!1N0V#301==-BQGNF(2.Z!775&VVYE/NY4H6[RK*9#-<">6JE0RZ9:
M"K5*VQ!8:E%-P!+XZ]</8(X@#9ID.:]**@ME2E90U-CKGCXPK29Q:"8J:,!:
M&:GYL<X9N-'[A)=@ *&G<X'#D>OW/:O6-*Z_@>4X!OU$V:.(C_=+D7:_[I&T
M>UG^VI9<I/T&"W&G=\)N)Z_^LD$TDL/U@+6 9?R(@$.+)>K!U;% *M?GR[;3
M*081P;! F@.TCPQL;.U=-/+WX$ZZFF)Q72.2Y&YQ>"@"&/(PZ)D3+U8=N;:G
MKT9+C&@$"O:=3#AD-1TRLLZ(@X9;FT6DW3!K8W-N,N/176Y=7)</KIHVRS;V
MBS5WX?!,WP//% ,+'^L(N04#S1$<>0/!2UZU0%^,L+H8C["Z/@;ZMJT)T236
MF>S.G<C:R:N_0SJ'"(!X10<C7ZIQZ>#,M[7D;AH%=5A.R7RB>9%I3F/[."AC
M(DW#<%2>B>M2Y662]-&"N70DDKB5S"/O$VI18ZR!ES>6FAZYIDP(H_=<7S8#
M>XN(%-!2RKF@H:E<:]HHV$<6*]IPC)JLDAE&RS#F2HS[*$9#5RPIJH!/3>I*
M@7N;S#268"_G)L.XEJ)/8.NQR*4FC$Z\9 &CB_$I7G4,3W(W(UY _"LFK\HX
M$D;-.1UEO_#3AQ5R05&"4''H3RVPAL?'OGD7".9#4S!-=RM9X"_4>[-H%\[(
M#)$\&<7#B=V<F8(L[.9MA/AX1/:3T70X/WU,ZW"U-QWB\W>)JYW2ACI>(1*3
MJN94NF_Y)B0P50>=O1Z@G!&;K(ZK@OG.1GU=/(FB;_O6"3DC^V%ALL:W-I2\
MD6N&"T(IFS.1PU3A'QP7X3J$\(C,HJG1BT0!4I,89.7A4U04P2=I1"ER^)PS
M@$-LT+'Z>/G$E&J<_KE.Y6#:!!9  N;:-C%R0OI2-JX-"*<!8B!=/!MI(G+]
MZU'B -\PUH^>)Y1S6YR**9E.JH^VW-C3_92#3_=)#I[YPK [&;@CJO-NJR>X
M-$R,I@NK$U>]TY-U\(./;$G%&A%Z"3L"E>SY#Y<NV,BPF4"A*O:.!S8Q5XG4
M5KL+C!_R(+MX6$J[!6ZWA"\SRQ.4,T39Q84C=4Q/7*Q=-0F.!T/KQI-T159U
M  MVR6.'6N$FS[F[$]&V8Q_:@EZBLV0D-TTIC<SP81%K++-!)Q/#>^ +L/TB
M5T$>=_+ZJ>@GXL"+"-_H9S P.;<-_\9\*Y,%@3B?M TQY7&Y#_X+!V]<A78P
M&&5K HN9&+#[*1A/CL<C&4^NE8P_4O,R/ X_J=6=<-R1*[]YAR=:^LH)))3)
M/J@%KB_?E#(YE2$_!*%U4%"DWBFL\4X[W_$M_.UWV'7X4B@VJ/44Y*3@?.JV
M<(W )?'@#$4:  >ZUQ&:+CY(YF)<>@ARD,"0+($Z'KQO0^C\>W(V+3C<&9FN
M\#[_KYVE\73I.1N%'17!(G!(1G7@E+M/H@; [6)/I<C)/DF1<RH9#V>8JZ#.
M,*Q R:T[P3(&P>)*#KR78X, R%W#3(DCNI@^;FO ;?0"3/UVLU:P2@Q8]'5E
MS%B!5H8FH*/@LGCT9MVIT^KY86 T2$M(-AQMGR(70Y_;IG&'COH3H*-V))\[
M1YR(GCF**H=6%8V@B.C$=NI5!Z(Z3N5?PFKF#@Q(L82('(JND?=AXGO($ KT
M!KIY_P72)>:1>Z7C0K"!!%N8$7-3NYP!83:NS!G<NTVGTQ&IV=-]4K-G8?->
M4Z>6NU90.\R^24EQ<E[."F/G"7)71";NC^>OB>(D[)G4"2R(3Q$-]!E6.>,E
M]A?P/"3AGDL \AX64&>*(?5_S#M?*Z7IG8,WX/.#*!.L\TVXQ'M F*2W^&Q$
MBJ],X41A")-X^F.,L'3PIA\<5-V1Z/F!416+JM9IJ.@@KPMY[R7H0VAW]/JR
MF-[ =<XF/CM6 QG\BF-BYPQV3=XXA"RM*PF,M;<!7_FN\#\HL,5>,WNT$%2Y
M1G/)"^*/IJ+UC<H8&(G@;=BS87L;W)@.;&R>V,V._<G]\:B(TWNGCZY6$2[O
M_0]IY'"G'W:F'ZQLQ7R70GL$QP!K=?--"4WI08;E8LJ2F<.GS&URJ4OCV7!]
MWI)[TQ!L=J+]J+TX>13^6F)?OQ!UVO^<V\F#\8BBZZW5M_H2:[^1J%UH<7[!
MZ%U])Y)V)I*N=/F<$RH4=):WK]#>9C E^:>&N84CL!)ML:L]],_H7UP:(XQ0
M)YO?QT_X"CPWT]C'GH)1*,DM1WR!":9"43=C^16A_#$=A]@ 2MF1A02VMB?+
MD+D*C<JR6C&!.#86RM=HSTB.D< +',$JJZAM8XY%^V LN4*FR!M/Q82E:+UI
MB)>4X]8U43=0#R:Q<4GX16@(C%E[$+*?:GK%7/=4D#W<)T'V'.F;09W _M[9
M4Z.(9$M.7WA_I:$OBBOAVI;-BGD +HW"MB'6P.R0QYHQ3@[,TY-]3+VI,(ED
MX!+!L%AO(PE]@?\$FNWN9:_*(#$M<FJS_T:!P3V]K8_VZ[9&-*S(G8](NIU>
MVR0Y0W]Y@2?3,E]5MP_$0 !D$M(8S+<''C6#8C82OH[V8#51V07H!_+S">;&
MG/VQI]X'K:F\6E+_/?J'%5SR]B["B%+!3T;-B'H=+0IAUZ.,#=; .5W+H6.X
M2E(BAX%K_3YC3 LSXU29$7N]C$!V_!:^(C#Z.C$)&&X@B)]\4>7YT0^U*B_
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M*"E";[E8T1I<LR'];:2TV=/HZ(S93EP;(O^2#G@9M)*@(KGG:F4;XF,JJ==
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M/#K^YN;_NU/0\<AW(!9YW54>_\PC<?'QTN*/L"CNW-<_O?O:R=T]?!#]AA:
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M\-YMO\>KY/>K\L/0YRZP/)B\ V,&%LW?5M_;7Y&^?W'GMV0CF1D^KBN[TZ8
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MXDYK<YN_7@4OPLA&-2W3B21(9D@VE*@LO28$E+T6F,1O6\8#Z[74>GU)A&E
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MIU;V^X?0WA..=-ML8UOMTPL=_!E0$!8:!8ET20&*V'9?/$!5'R0#DM%.O&\
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M_^%\,5,EF>8S5+JT-6_9;.QK+&_:;E+OBK((Z_S]W5J":'+Z,VY%/2E13[C
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M(&F9ZYNJD@'3!3JO3/ZE*KFTA'F'3H0CW\6FNRSZWGP9ZV@\OEX6MPK'+\U
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M6>ZZ-,5+U&L@IQX>K%S3PPI2H (=D6*R'?7M#X3P!X\(X7^B]HS(HU^KFT>
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M; T?T,<B^NC>,JGCOL4>!JO<VQO2/QZ$-C81$T<&'^* 'S[S@6<_'@8 W@]
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MHO<ZW<8H[:&1TP9BV\@YN"^_& ]R;\A+=EN:^* I^'N8R1!+L$\7]LP<TR=
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MSF;$3I#K 0C**I96ZP7^F>A56FD-?PVQJ0\YS3;);NGK%>A_>:W*E.8&$!W
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MW2F9#*L-X 98#$]JTFI.@,7S8G@] =*8CH8TK)UR%7#5*2)$II-KW8??3@/
MH2Y(,[=1!:RMFJ4Z5.R*299>RTCUXH8I &=+KU=%B!GVZ2*!8"<=L+!\OVI0
MZI5FL!=/T?7?V3*O\-);7\KPC!E/UM0L00'T3P#EDM&@G.'&%Q^)$R;F:'O4
M)#Q"/ .Q#YB+34%G [8%5C,-5R*[&345GO-8IBN<9^.F2QE](AC[92RPW>A,
M9LD!MI+FV+,*RRGI?6Z TX!*M95NDZ8QG98-ST.*P/#C*62"FCZ:$MK=I/B>
M1@_K85MF:D\EH^."<3RHL20X%"<U!@58_AD.EQ0! 'IJLS0N"+K!S*."C8$M
M&WV+]#R=2,^FS.F!1B*A/Z$DX\",J@M0'=2<>KJ[C42RE3(MH=^AQ)E;GC6"
M/'61IS.XD9!ZC?<,/UM'C6CL1!7&CV.^,\X'G"MKYH_9=YL!L4Y^A&/U4%F[
M5GGZFV)^@E=<X\TT#!:XR+3AL8[A@YZ H_U@9+)EG:/]'%21)F.+D!6-,Z#M
M,M<R@?1?XHR\[4;K'L0I'UWY?LX$E?XJ%#Q$'[0IW@\Z1V1+1K>:SHN"]"T0
MCSS9%-5P'O7H*]W\MHVLG#E/],.5L# D?[ 9,7@-DH&G;1;+95'638Y$5=.4
MP!0@T_9,X<1('D )Y)P9'TY;$(.$MX,)>1Q<W-ER:PLT5?*.?<!26.R"-ND4
M5@-7;TAN>SV5KM&%P2[%ULIV[Z%-^U-K)UHBBD5XRG=% _K\^:0_50TRN93]
MXGX@@DZ#1E*3>HQ\<@*_,D3Q?'SEG0'4-MM<4'+2U#S,G)UL]X-8Z\RLRSQ$
M-1#J;2/17\'FKV/3P4<*U,/0V# .)GXII0Z0]5ZT$78&?R"6>J$+?JIQ.TT+
M74[A;4^ NQ\^(N[>CJXC1W^O5P7K" _/R(=YP@#2>]P4$?EV9X:;VSHZWHX2
MT&O!9B@1^<6_8_DKN["8VIG%E 6(#K;#9Y_(?M>SNV![UAE[GVVR=.O$0?O%
M36TFSG9($QU5$=@Z:4$S=-%.RJ.M$P$81VB,^$O;(F\=KR9'W1P9)/ND!E80
MXS6+IJI!Y8MHIK&,IR;W/;Z9]TA^$#;-M+%C_7WGP9CL8VK1M[<7+7<7(%L4
M&)1E'B&*8GB6IBK3_-LY;+6>TV:-:"@M 0A8=J-7,WR\C,BUOQ;3:5-6_8??
MXZ%CO_L$"!$6H2WER7((^6$US\UJ9D664=B7W3WDRK0!\4 +>?P\\^@1\<Q+
M<B2PW?.P'/*58,Z*=*ZY.."*G-S@BZ*T-MA:;F;0$L@P2T2E2O,5V-[ Y=(L
MT]=LFS6YQJ#35*/AR4A/%P$8XHBN0IV5O$7F.ID+;<AJH5)2B^2+]A)0'THY
MD'5#$] Q+FCCTBE0.>A>%,\J]>0IV(''CPCK?R++'+G1:W7ST(I!6QHSWI,$
M-6X##I)6=<F?$IT!KT7TL88!HA'&PEM)%2:AP$OI8-I:,$Y.%,K<9DEQY!+]
MD.*4I_'G*(&BKOY[DS*)L7^#9%=LE8Z:_)[&DYD0#9#+A_P@'&!%>L&P6(F.
MDDS=6*_(98UOA ^<_N@"N:7)&"#!VV2ZDD K^Y'@Q;,LG;)[!1_X!.CIV2.B
MIXN\1DMR-$Z34",;MI EH8")S64R,;J5)F8[_ !"^+1N:AY-KQD,*GA!*R-"
M9)@J.<D)S6TS]E[,YJJ9_(H?)2=(,F0HUP&]^$"PJ)T"";(_QT_ 4F6I\FO9
M1.?E54\2A@F0>(LR7B??72 :-<O31'-L#N,;-<=V<5LN7G</M5I<,"@M@:!O
M"40L-?W<.9+U-I>D,K&[,+VN[:.%PYD*E\>O,7%(3H"\:0SSIZA_GCPBSG&.
MR86Z1-2KQL0UC(!D2T4GG"CDUAK;Q$VVOJW>F>#]*,,!85/ %Y!PZ!ZC>/C,
MFNJ2?,IW>5P$U5W#E2K,=712?V/$]-'PBV#A9A!]]2;ZY=75FXO+R^B7OU^\
MOWC[8QRP/M98.&IJH=SV35C- #.;*\\),=%@3G9!,KY2FC=O__7V_)_O+Z*M
M5Y?OSRY>;T>OKUX.+?QK+^Y_[ORO&QI^F)7^<$LND&^1ZB<4J7X@@@2V.H!+
M#U1LE]89K^BS%>H^S$:"^K)'L-X[6-](5HFQC(30HV=)CXG[_?>D2&[AGWF]
MR/[V_P-02P$"% ,4    " #3GI!9II+&NT9#   [LP$ 'P
M@ $     8V5O96UP;&]Y;65N=&%G<F5E;65N=&5X,3 Q+FAT;5!+ 0(4 Q0
M   ( -.>D%E)Z? A,!<  "B"   1              "  8-#  !N=F-R+3(P
M,C0P.#,P+FAT;5!+ 0(4 Q0    ( -.>D%G4_<>H=@(  %H'   1
M      "  >):  !N=F-R+3(P,C0P.#,P+GAS9%!+ 0(4 Q0    ( -.>D%D-
M-XSY+0H  "E5   5              "  8==  !N=F-R+3(P,C0P.#,P7VQA
M8BYX;6Q02P$"% ,4    " #3GI!9X1=9X;(&   C,0  %0
M@ 'G9P  ;G9C<BTR,#(T,#@S,%]P<F4N>&UL4$L! A0#%     @ TYZ065PV
MOQR.60  ?"X" !X              ( !S&X  '-E;FEO<F%D=FES;W)T;V-E
C;V5M<&QO>6UE+FAT;5!+!08     !@ & )T!  "6R      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>nvcr-20240830_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nvcr-20240830.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001645113</identifier>
        </entity>
        <period>
            <startDate>2024-08-26</startDate>
            <endDate>2024-10-31</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-21">0001645113</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-22">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K/A</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2024-08-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">NovoCure Limited</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">Y9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-37565</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">98-1057807</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">No. 4 The Forum, Grenville Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">St. Helier</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-9">JE</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">JE2 4UF</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">44 (0) 15</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">3475 6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="c-1" id="f-13">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-14">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-15">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-16">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Ordinary Shares, no par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">NVCR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
